<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of convulsive status epilepticus in children</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of convulsive status epilepticus in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of convulsive status epilepticus in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Angus Wilfong, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas R Nordli, Jr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Torrey, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James F Wiley, II, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Generalized convulsive status epilepticus (SE) is a serious and potentially life-threatening medical emergency that requires prompt intervention.</p><p>The management of SE in children is reviewed here. The definition, pathophysiology, risk factors, and outcome of this disorder are discussed separately. (See  <a class="medical medical_review" href="/d/html/6222.html" rel="external">"Clinical features and complications of status epilepticus in children"</a>.)</p><p class="headingAnchor" id="H1396165717"><span class="h1">DEFINITION AND DIFFERENTIAL DIAGNOSIS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Status epilepticus</strong> – An accepted definition for the purposes of clinical practice defines SE as either a single unremitting seizure lasting longer than five minutes or as frequent clinical seizures without an interictal return to the baseline clinical state. The five-minute window corresponds with the time at which urgent treatment should begin. If SE continues beyond 30 minutes, then long-term consequences including neuronal injury, alteration of neuronal networks, and neuronal death can occur. (See  <a class="medical medical_review" href="/d/html/6222.html" rel="external">"Clinical features and complications of status epilepticus in children", section on 'Definition'</a>.)</p><p></p><p class="bulletIndent1">SE is categorized according to whether seizure activity is focal or generalized. In many cases, however, generalized convulsive SE cannot be separated easily into cases with a primarily generalized onset versus those with focal onset and secondary generalization. Both generalized and focal SE can be further classified according to whether clinical seizure activity is convulsive or nonconvulsive  (<a class="graphic graphic_table graphicRef97140" href="/d/graphic/97140.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Convulsive status epilepticus</strong> – Convulsive SE is the focus of this topic and is a clinical diagnosis, confirmed in most cases by the presence of sustained and rhythmic generalized tonic and clonic motor activity lasting for longer than five minutes or repetitive convulsive seizures without a return to baseline consciousness between seizures. Although the diagnosis of convulsive SE is usually obvious, a detailed neurologic examination is important in making the diagnosis of more subtle or focal forms of SE.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonconvulsive status epilepticus</strong> – Nonconvulsive SE is defined as status epilepticus without prominent motor symptoms. (See  <a class="medical medical_review" href="/d/html/14103.html" rel="external">"Nonconvulsive status epilepticus: Classification, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Brief generalized seizures</strong> – Children with brief, generalized motor seizures and relatively preserved interictal consciousness are <strong>not</strong> considered to have SE; most of these patients will not be seizing on arrival to the emergency department and do not require emergency intravenous medication [<a href="#rid1">1</a>]. Common scenarios include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Febrile seizures</strong> – Febrile seizures are the most common type of brief, generalized seizures in children and, in the absence of signs of meningitis or encephalitis, do not require extensive laboratory evaluation or anticonvulsant therapy. (See  <a class="medical medical_review" href="/d/html/6183.html" rel="external">"Clinical features and evaluation of febrile seizures"</a> and  <a class="medical medical_review" href="/d/html/96573.html" rel="external">"Treatment and prognosis of febrile seizures"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>First-time afebrile seizure</strong> – A first afebrile seizure requires a careful history, physical examination, and focused evaluation to exclude nonepileptic medical conditions that may have provoked the seizure, such as fever, serious infection, head trauma, hypoglycemia, electrolyte disturbance, cardiac arrhythmia, or a space-occupying intracranial lesion.</p><p></p><p class="bulletIndent2">If an acute medical cause cannot be found during the emergency department visit, then the child may be experiencing the initial seizure of an epileptic disorder. These patients warrant referral to a pediatric neurologist. Most children diagnosed with an unprovoked seizure or epilepsy of unknown etiology will need a scheduled electroencephalography (EEG) and neuroimaging, preferably with magnetic resonance imaging. (See  <a class="medical medical_review" href="/d/html/6199.html" rel="external">"Seizures and epilepsy in children: Classification, etiology, and clinical features"</a> and  <a class="medical medical_review" href="/d/html/6203.html" rel="external">"Seizures and epilepsy in children: Initial treatment and monitoring"</a>.)</p><p></p><p class="bulletIndent2">Children with a first, unprovoked seizure, particularly patients with a normal EEG and neuroimaging, do not typically receive anticonvulsant medications. (See  <a class="medical medical_review" href="/d/html/6203.html" rel="external">"Seizures and epilepsy in children: Initial treatment and monitoring", section on 'First unprovoked seizure'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Breakthrough seizures in children with known epilepsy</strong> – Children with a known seizure disorder may have brief, breakthrough convulsive seizures that are commonly caused by an intercurrent illness or subtherapeutic anticonvulsant levels. Many of these patients can be managed by adjustment of oral anticonvulsant therapy after consultation with the prescribing pediatric neurologist.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Focal seizures</strong> – Seizures that are not generalized convulsive (tonic, clonic, tonic-clonic) require a different approach to evaluation and treatment, as discussed separately. (See  <a class="medical medical_review" href="/d/html/2231.html" rel="external">"Focal epilepsy: Causes and clinical features"</a> and  <a class="medical medical_review" href="/d/html/6203.html" rel="external">"Seizures and epilepsy in children: Initial treatment and monitoring"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychogenic nonepileptic seizures</strong> – Psychogenic nonepileptic seizures (PNES) are usually dramatic behavioral events in a conscious individual that are often misdiagnosed as epileptic seizures and are sometimes treated with large doses of antiseizure medications. The history and presentation may provide clues to diagnosis. PNES typically occur in teenage patients, predominately in females, with affective or anxiety disorders, and a family history of seizures may be present. Many patients who have PNES also have or have had epileptic seizures, so a past medical history of PNES should not be used to rule out the possibility of epileptic status. PNES include a variety of clinical manifestations, some of which are suggestive, although not independently diagnostic, in distinguishing PNES from other differential diagnoses  (<a class="graphic graphic_table graphicRef131637" href="/d/graphic/131637.html" rel="external">table 2</a>); these are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2227.html" rel="external">"Psychogenic nonepileptic seizures: Etiology, clinical features, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1">In many patients, PNES can be distinguished from SE based upon clinical features or responsiveness to brief, painful stimuli (eg, nailbed pressure). When there is clinical uncertainty, PNES can be definitively distinguished from SE by an urgent EEG (see <a class="local">'Electroencephalography'</a> below). Therapy may need to be initiated before an EEG can be obtained, especially in patients with prior epileptic seizures. In this case, sedating medication should be avoided, if possible. <a class="drug drug_pediatric" data-topicid="13327" href="/d/drug information/13327.html" rel="external">Fosphenytoin</a> or <a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">valproate</a> are reasonable alternatives to benzodiazepines in this setting.</p><p></p><p class="bulletIndent1">PNES and other nonepileptic paroxysmal disorders are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6155.html" rel="external">"Nonepileptic paroxysmal disorders in children"</a> and  <a class="medical medical_review" href="/d/html/2227.html" rel="external">"Psychogenic nonepileptic seizures: Etiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H976880450"><span class="h1">RAPID RECOGNITION OF STATUS EPILEPTICUS</span><span class="headingEndMark"> — </span>The diagnosis of convulsive SE is clinical and is confirmed by verifying the presence of either an unremitting generalized seizure lasting longer than five minutes or frequent seizures without an interictal return to the baseline level of consciousness. (See <a class="local">'Definition and differential diagnosis'</a> above.)</p><p>Patients with generalized motor seizures that are frequent or separated by a period of significantly impaired consciousness or who are medically unstable require immediate assessment and treatment in an acute care setting (emergency department or intensive care unit).</p><p class="headingAnchor" id="H3716447773"><span class="h1">URGENT FOCUSED EVALUATION</span><span class="headingEndMark"> — </span>During the course of resuscitation, the clinician or designee should obtain a focused history from a parent or caregiver to determine:</p><p class="bulletIndent1"><span class="glyph">●</span>Prehospital administration of benzodiazepines and any other antiseizure medications</p><p class="bulletIndent1"><span class="glyph">●</span>Patient history of epilepsy</p><p class="bulletIndent1"><span class="glyph">●</span>Precipitating factors prior to seizure (eg, febrile illness, possible toxic exposure, trauma, change in antiseizure medications) (see  <a class="medical medical_review" href="/d/html/6222.html" rel="external">"Clinical features and complications of status epilepticus in children", section on 'Causes'</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Current medications, including prior or current use of antiseizure medications</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with prior SE, history of treatment response (see <a class="local">'Factors influencing choice of agent'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Other active medical diagnoses, especially those associated with hypoglycemia  (<a class="graphic graphic_table graphicRef103015" href="/d/graphic/103015.html" rel="external">table 3</a>), hyponatremia, or hypocalcemia  (<a class="graphic graphic_table graphicRef53781" href="/d/graphic/53781.html" rel="external">table 4</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Allergies to any medications</p><p></p><p class="bulletIndent1">In patients with SE, the initial physical examination is limited. In addition to assessing vital signs, airway, breathing, and circulation, the clinician should identify:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Signs of head trauma (eg, swelling, ecchymosis, or lacerations)</p><p class="bulletIndent1"><span class="glyph">●</span>Signs of sepsis or meningitis (eg, fever, poor perfusion, or rash [eg, petechiae, erythroderma, or cellulitis])</p><p class="bulletIndent1"><span class="glyph">●</span>Seizure characteristics (eg, focal or generalized) (see  <a class="medical medical_review" href="/d/html/6222.html" rel="external">"Clinical features and complications of status epilepticus in children", section on 'Classification'</a>)</p><p></p><p class="headingAnchor" id="H477270356"><span class="h1">IMMEDIATE SUPPORTIVE CARE</span></p><p class="headingAnchor" id="H1519042913"><span class="h2">Approach</span><span class="headingEndMark"> — </span>In children with convulsive SE, rapid supportive care must occur simultaneously with prompt administration of antiseizure medications  (<a class="graphic graphic_algorithm graphicRef131955" href="/d/graphic/131955.html" rel="external">algorithm 1</a>).</p><p>The main goals of treatment are [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Establish and maintain adequate airway, breathing, and circulation (see <a class="local">'Airway and breathing'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Identify and treat hypoglycemia  (<a class="graphic graphic_table graphicRef83485" href="/d/graphic/83485.html" rel="external">table 5</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Stop the seizure and thereby prevent brain injury (see <a class="local">'Emergency antiseizure treatment'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Identify and treat life-threatening causes of SE such as trauma, sepsis, meningitis, encephalitis, or structural brain lesion</p><p></p><p class="headingAnchor" id="H564077088"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>All patients with generalized convulsions should have continuous monitoring of heart rate and rhythm, breathing, and pulse oximetry along with periodic measurement of blood pressure and temperature. However, myoclonic jerks may interfere with the ability of electronic monitors to detect abnormalities. Thus, frequent clinical assessment of breathing, pulse, and color must supplement monitor readings to ensure rapid detection of apnea, cyanosis, or shock.</p><p class="headingAnchor" id="H961532371"><span class="h2">Airway and breathing</span><span class="headingEndMark"> — </span>Important airway interventions in children with SE include:</p><p class="bulletIndent1"><span class="glyph">●</span>Open the airway and maintain it through positioning  (<a class="graphic graphic_picture graphicRef70710" href="/d/graphic/70710.html" rel="external">picture 1</a>), jaw thrust  (<a class="graphic graphic_picture graphicRef51547" href="/d/graphic/51547.html" rel="external">picture 2</a>), and/or airway adjuncts (eg, nasopharyngeal  (<a class="graphic graphic_picture graphicRef79849" href="/d/graphic/79849.html" rel="external">picture 3</a>) or oropharyngeal  (<a class="graphic graphic_picture graphicRef77645" href="/d/graphic/77645.html" rel="external">picture 4</a>) airways) as needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suction secretions using a Yankauer (tonsil tip) suction catheter; have an additional large-bore suction device available in case the patient vomits.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administer 100 percent oxygen; use pulse oximetry and visual appearance to assess for cyanosis. When feasible, quantitative, sidestream end-tidal CO<sub>2</sub> (EtCO<sub>2</sub>) monitoring can help supplement the visual assessment of respiratory rate and ventilation when the wave form is used to interpret the EtCO<sub>2</sub> reading. Myoclonus may interfere with the accuracy of monitor readings.</p><p></p><p class="bulletIndent1">For children with transient apnea or hypoxemia, the clinician may use bag-mask ventilation as long as the airway can be maintained and spontaneous breathing with adequate oxygenation resumes within a short period of time. Two rescuers are typically necessary to maintain the airway during bag-mask ventilation in children with SE  (<a class="graphic graphic_picture graphicRef72516" href="/d/graphic/72516.html" rel="external">picture 5</a>).</p><p></p><p class="bulletIndent1">The patients with any one of the following should undergo rapid sequence endotracheal intubation (RSI) and mechanical ventilation:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unprotected or unmaintainable airway</p><p class="bulletIndent1"><span class="glyph">●</span>Apnea or inadequate ventilation</p><p class="bulletIndent1"><span class="glyph">●</span>Hypoxemia</p><p class="bulletIndent1"><span class="glyph">●</span>SE lasting 30 minutes</p><p></p><p>The tables provide a rapid overview of RSI in children  (<a class="graphic graphic_table graphicRef51456" href="/d/graphic/51456.html" rel="external">table 6</a>) and initial settings for volume-controlled  (<a class="graphic graphic_table graphicRef113548" href="/d/graphic/113548.html" rel="external">table 7</a>) and pressure-controlled  (<a class="graphic graphic_table graphicRef113549" href="/d/graphic/113549.html" rel="external">table 8</a>) mechanical ventilation. Emergency endotracheal intubation in children and pediatric RSI are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6316.html" rel="external">"Technique of emergency endotracheal intubation in children"</a> and  <a class="medical medical_review" href="/d/html/6390.html" rel="external">"Rapid sequence intubation (RSI) in children for emergency medicine: Approach"</a>.)</p><p class="bulletIndent1">Special considerations for children with SE undergoing RSI include:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12741" href="/d/drug information/12741.html" rel="external">Propofol</a> and <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a> have antiepileptic properties, and either agent may be used for induction in hemodynamically stable patients. Propofol has a shorter onset of clinical effect.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Short-acting muscle relaxants, either <a class="drug drug_pediatric" data-topicid="12774" href="/d/drug information/12774.html" rel="external">rocuronium</a> or, in patients without contraindications, <a class="drug drug_pediatric" data-topicid="12809" href="/d/drug information/12809.html" rel="external">succinylcholine</a> should be given so that visual confirmation of continued seizures is preserved once the brief paralysis resolves. However, an urgent EEG should be obtained to look for electrographic seizures if prolonged paralysis is indicated, as may be the case for patients with hyperthermia or rhabdomyolysis.</p><p></p><p class="headingAnchor" id="H3511470910"><span class="h2">Circulation and vascular access</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Establish venous access</strong> – Patients with SE require timely vascular access for sampling of blood and administration of medications and fluids. Peripheral intravenous (IV) access should be established as soon as possible. Alternative routes of antiseizure medication administration (eg, rectal, intramuscular, buccal, or intranasal) should be used if IV administration is not possible within the first five minutes; an intraosseous (IO) line should be placed if IV access is further delayed.</p><p></p><p class="bulletIndent1">For patients whose seizures do not resolve with benzodiazepine therapy, a second IV access should be obtained to facilitate the administration of two separate antiseizure medications and/or continuous anesthetic infusions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemodynamic support</strong> –<strong> </strong>Most children with SE initially have elevated blood pressure and do not require circulatory support. Heart rate and blood pressure may be elevated in patients with SE but typically normalize once seizures resolve [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1">In general, SE does not independently cause systemic hypotension. The presence of low blood pressure in children presenting with SE should prompt consideration of an underlying systemic illness, traumatic hemorrhage, or infection. These patients warrant rapid infusion of isotonic crystalloid (eg, normal <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> or Ringer lactate) and further treatment based upon the type of shock that is present  (<a class="graphic graphic_algorithm graphicRef129655" href="/d/graphic/129655.html" rel="external">algorithm 2</a>). (See  <a class="medical medical_review" href="/d/html/6397.html" rel="external">"Shock in children in resource-abundant settings: Initial management"</a>.)</p><p></p><p class="bulletIndent1">In addition, the presence of bradycardia, hypotension, and poor perfusion are warning signs that point to hypoxia. Children with these signs require immediate attention to improve oxygenation and ventilation and, if not already done, RSI with mechanical ventilation [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1">Clinicians should anticipate hypotension for children who require continuous infusions of medications for refractory SE. Rapid infusion of isotonic crystalloid (eg, 20 mL/kg of normal <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> or Ringer lactate) followed by a continuous infusion of a vasopressor such as <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a> or <a class="drug drug_pediatric" data-topicid="12650" href="/d/drug information/12650.html" rel="external">norepinephrine</a> are frequently necessary to maintain adequate tissue perfusion and blood pressure.</p><p></p><p class="headingAnchor" id="H2329314077"><span class="h2">Initial studies</span><span class="headingEndMark"> — </span>Initial blood and urine studies should be obtained for rapid determination of:</p><p class="bulletIndent1"><span class="glyph">●</span>Plasma glucose and a rapid "finger-stick" or point-of-care glucose</p><p class="bulletIndent1"><span class="glyph">●</span>Serum electrolytes and calcium</p><p class="bulletIndent1"><span class="glyph">●</span>Serum antiseizure medication levels, if applicable</p><p class="bulletIndent1"><span class="glyph">●</span>If substance use or poisoning is suspected, urine and blood toxicology</p><p class="bulletIndent1"><span class="glyph">●</span>In postmenarchal females, qualitative pregnancy test (urine or blood)</p><p></p><p>Other studies may also be indicated based upon the most likely underlying cause. (See <a class="local">'Additional studies'</a> below.)</p><p>Plasma glucose, serum electrolytes, and antiseizure medication serum levels (for children receiving them) are the most helpful in guiding initial care for children with SE. In a systematic review of 20 observational studies (almost 2100 children with SE), the yield of preliminary testing was as follows [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>6 percent had abnormal electrolyte or glucose levels</p><p class="bulletIndent1"><span class="glyph">●</span>3.6 percent had evidence of toxin ingestion</p><p class="bulletIndent1"><span class="glyph">●</span>Of children receiving antiseizure medications, almost 33 percent had subtherapeutic levels</p><p></p><p>While the yield of routine measurement of electrolytes, glucose, and qualitative toxin screens was relatively low in this study, abnormal findings affect management strategies and outcomes. The utility and interpretation of testing for drugs of abuse screen is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/13846.html" rel="external">"Testing for drugs of abuse (DOAs)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electroencephalogram (EEG)</strong> – When there is uncertainty regarding the presence of SE, an urgent portable EEG should be obtained. In the emergency department, this can be a limited study, with application of only a few electrodes to determine if the background is consistent with a normal awake individual (ie, psychogenic nonepileptic seizure) or the diffusely slow and depressed background of SE. (See  <a class="medical medical_review" href="/d/html/2227.html" rel="external">"Psychogenic nonepileptic seizures: Etiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1">If an urgent EEG cannot be obtained, or is not considered necessary in the case of an obvious clinical diagnosis of convulsive SE, an EEG should still be done to evaluate background activity as soon as possible after the seizure stops for patients with first-ever seizures or convulsive SE. Patients with known epilepsy who return to baseline may not require an EEG. (See <a class="local">'Electroencephalography'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuroimaging</strong> – Neuroimaging is generally deferred until the patient is stabilized. (See <a class="local">'Neuroimaging'</a> below.)</p><p></p><p class="headingAnchor" id="H3424967032"><span class="h2">Correct hypoglycemia and metabolic abnormalities</span><span class="headingEndMark"> — </span>Hypoglycemia may provoke seizures and convulsive SE. Although uncommon, either severe hyponatremia or hypocalcemia may cause SE that is refractory to antiseizure medication and requires timely correction. Metabolic acidosis is often present in patients with SE and can be severe, but it usually resolves without treatment once seizures are controlled.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypoglycemia</strong> – All children with SE should have measurement of a fingerstick or rapid point-of-care measurement of plasma glucose as soon as possible. In children with SE, including those who are just initiating the ketogenic diet for seizure control, hypoglycemia should be treated as outlined in the rapid overview table  (<a class="graphic graphic_table graphicRef83485" href="/d/graphic/83485.html" rel="external">table 5</a>). For patients who are stable on the ketogenic diet for seizure control and present in SE, a plasma glucose ≤40 mg/dL (2.2 mmol/L) warrants treatment for hypoglycemia. Continued seizures, especially in the setting of hypoxemia, may lower brain glucose levels as the metabolic demands outstrip the supply, worsening brain lactic acidosis and leading to further neuronal damage if prolonged; this emphasizes the importance of ensuring adequate plasma glucose levels [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/5805.html" rel="external">"Approach to hypoglycemia in infants and children"</a> and  <a class="medical medical_review" href="/d/html/14438.html" rel="external">"Ketogenic dietary therapies for the treatment of epilepsy"</a>.)</p><p></p><p class="bulletIndent1">Children with diabetes and hypoglycemia may present in the emergency department with generalized or focal seizures, or focal syndromes such as hemitonic posturing and hemiparesis, which may mimic seizures or a postictal state, respectively. These children should be treated with glucose, not anticonvulsants. This situation emphasizes the importance of obtaining a rapid assessment of blood glucose in a child with seizures in order to provide appropriate therapy.</p><p></p><p class="bulletIndent1">Most children with acute seizures have elevated blood glucose levels that do not require treatment. However, nonketotic or ketotic hyperglycemia can occasionally precipitate SE and may be an early manifestation of diabetes [<a href="#rid5">5,6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyponatremia</strong> – Severe symptoms, including seizures, are most commonly seen in children with severe hyponatremia (serum sodium &lt;120 mEq/L) that develops acutely (over less than 48 hours). Initial therapy consists of 3 to 5 mL/kg of 3 percent <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> administered over 15 minutes. After the initial hypertonic saline infusion, point-of-care serum sodium should be remeasured and, if seizures are ongoing, the infusion should be repeated. (See  <a class="medical medical_review" href="/d/html/120083.html" rel="external">"Hyponatremia in children: Evaluation and management", section on 'Acute symptomatic hyponatremia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypocalcemia</strong> – Seizures in the setting of hypocalcemia require therapy with IV calcium. The recommended dose of elemental calcium is 5 to 7 mg/kg. Dosing in this range can be achieved by giving 0.6 mL/kg of <a class="drug drug_pediatric" data-topicid="12956" href="/d/drug information/12956.html" rel="external">calcium gluconate</a> 10 percent, which provides 5.6 mg/kg <strong>of elemental</strong> calcium or 0.2 mL/kg of <a class="drug drug_pediatric" data-topicid="12651" href="/d/drug information/12651.html" rel="external">calcium chloride</a> 10 percent (must be given through a central venous line), which provides 5.4 mg/kg <strong>of elemental</strong> calcium. The maximum single dose is 540 mg <strong>of elemental</strong> calcium. The calcium should be administered over 5 to 10 minutes in patients with spontaneous circulation. (See  <a class="medical medical_review" href="/d/html/6386.html" rel="external">"Primary drugs in pediatric resuscitation", section on 'Calcium'</a>.)</p><p></p><p>The causes of hyponatremia or hypocalcemia in children are discussed separately. (See  <a class="medical medical_review" href="/d/html/120083.html" rel="external">"Hyponatremia in children: Evaluation and management"</a> and  <a class="medical medical_review" href="/d/html/5846.html" rel="external">"Etiology of hypocalcemia in infants and children"</a>.)</p><p class="headingAnchor" id="H3657552873"><span class="h2">Temperature control</span><span class="headingEndMark"> — </span>Fever at presentation lowers the seizure threshold and requires treatment with <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> in children with SE.</p><p>Ongoing monitoring of temperature is essential to detect hyperthermia associated with excess muscle activity during SE. If present, then the resuscitation team should rapidly stabilize airway, breathing, and circulation, and initiate cooling measures (eg, evaporative cooling supplemented by a cooling blanket) and assess for rhabdomyolysis and end-organ damage. Antipyretics are ineffective. Hyperthermia and rhabdomyolysis caused by persistent SE may require rapid sequence intubation and ongoing paralysis and necessitate continuous portable EEG monitoring to guide seizure management. (See  <a class="medical medical_review" href="/d/html/6596.html" rel="external">"Heat stroke in children", section on 'Hospital management'</a> and  <a class="medical medical_review" href="/d/html/6596.html" rel="external">"Heat stroke in children", section on 'Diagnostic evaluation'</a>.)</p><p class="headingAnchor" id="H3008544302"><span class="h2">Suspicion for isoniazid poisoning</span><span class="headingEndMark"> — </span>In addition to benzodiazepine administration, children with SE possibly due to <a class="drug drug_pediatric" data-topicid="13393" href="/d/drug information/13393.html" rel="external">isoniazid</a> poisoning should receive <a class="drug drug_pediatric" data-topicid="12753" href="/d/drug information/12753.html" rel="external">pyridoxine</a> 70 mg/kg IV, up to 5 g at a rate of 0.5 per minute, which should be repeated if seizures continue. A dose of 1 gram pyridoxine per gram of isoniazid ingested can be used (and may be necessary) after ingestion of a known quantity of isoniazid. (See  <a class="medical medical_review" href="/d/html/316.html" rel="external">"Isoniazid (INH) poisoning"</a>.)</p><p class="headingAnchor" id="H18020037"><span class="h1">EMERGENCY ANTISEIZURE TREATMENT</span></p><p class="headingAnchor" id="H1580636534"><span class="h2">Approach</span><span class="headingEndMark"> — </span>Although many protocols are available for treatment of pediatric SE, comparative data are limited, and these approaches have not been validated by clinical trials [<a href="#rid7">7-9</a>]. The approach presented below applies to children older than four weeks of age (ie, <strong>not</strong> newborns) with generalized convulsive SE (tonic-clonic, clonic, or tonic) is generally consistent with guidelines published by the Neurocritical Care Society [<a href="#rid8">8</a>]. The overall treatment approach is summarized in the algorithm  (<a class="graphic graphic_algorithm graphicRef131955" href="/d/graphic/131955.html" rel="external">algorithm 1</a>). The treatment of neonatal seizures is discussed separately. (See  <a class="medical medical_review" href="/d/html/6201.html" rel="external">"Treatment of neonatal seizures"</a>.)</p><p>Clinically obvious convulsive SE should be treated <strong>immediately</strong> with a benzodiazepine, without waiting for an EEG or other studies. Treatment delay is associated with increased morbidity and mortality [<a href="#rid10">10-12</a>]. (See <a class="local">'First therapy: Benzodiazepines'</a> below.)</p><p>If seizures continue for 10 minutes after at least two injections of a benzodiazepine, a second therapy with a long-acting antiseizure medication should be given  (<a class="graphic graphic_table graphicRef55368" href="/d/graphic/55368.html" rel="external">table 9</a>). (See <a class="local">'Second therapy: Antiseizure medications'</a> below.)</p><p>In patients with ongoing convulsive SE lasting longer than 30 minutes despite two initial doses of benzodiazepine and a second therapy antiseizure medication, preparation for a continuous infusion of <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a> or <a class="drug drug_pediatric" data-topicid="12693" href="/d/drug information/12693.html" rel="external">pentobarbital</a> should occur simultaneously with administration of a different antiseizure medication. At this stage, the patient will require endotracheal intubation and mechanical ventilation (if not already performed), neurologic consultation, and transfer to a pediatric intensive care unit with continuous EEG monitoring capability, as described below. (See <a class="local">'Refractory status epilepticus'</a> below.)</p><p>There is controversy about whether to treat nonconvulsive SE (NCSE) as aggressively as convulsive SE. In all patients with NCSE, a concerted effort should be made to diagnose and treat seizures as quickly as possible but with minimal sedation to avoid inducing or prolonging coma and respiratory depression that requires endotracheal intubation and mechanical ventilation. In general, any fluctuating or unexplained alteration in behavior or mental status warrants consideration of NCSE and evaluation with EEG. The evaluation and treatment of NCSE is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/14103.html" rel="external">"Nonconvulsive status epilepticus: Classification, clinical features, and diagnosis", section on 'Evaluation'</a> and  <a class="medical medical_review" href="/d/html/129547.html" rel="external">"Nonconvulsive status epilepticus: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H3509009431"><span class="h2">First therapy: Benzodiazepines</span><span class="headingEndMark"> — </span>For children presenting with convulsive SE, we recommend immediate treatment with a benzodiazepine  (<a class="graphic graphic_algorithm graphicRef131955" href="/d/graphic/131955.html" rel="external">algorithm 1</a>). Benzodiazepines are the first-line treatment for SE because they can rapidly control seizures (see <a class="local">'Benzodiazepine efficacy and pharmacokinetics'</a> below). The three most commonly used benzodiazepines to treat SE are <a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a>, <a class="drug drug_pediatric" data-topicid="13223" href="/d/drug information/13223.html" rel="external">diazepam</a>, and <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a>.</p><p>Prior to hospital arrival, benzodiazepine treatment may occur in the home or be performed by emergency medical services according to prehospital, pediatric seizure protocols. In these patients, the first dose of benzodiazepines given in the hospital counts as the second dose of benzodiazepines as long as prehospital dosing was appropriate and, in children who continue with SE, a second antiseizure medication should be given  (<a class="graphic graphic_table graphicRef55368" href="/d/graphic/55368.html" rel="external">table 9</a>).</p><p class="headingAnchor" id="H524209480"><span class="h3">Prehospital treatment</span><span class="headingEndMark"> — </span>Treatment of SE out-of-hospital by prehospital emergency responders appears to be safe and effective in children. Intramuscular (IM) <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a> (5 mg for children whose weight is 13 to 40 kg and 10 mg for those over 40 kg) or intravenous (IV) <a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a> (0.1 mg/kg) can be safely and effectively used in this setting. Additional options include intranasal midazolam, 0.2 mg/kg of parenteral solution per dose, or buccal midazolam, 0.3 to 0.5 mg/kg. (See <a class="local">'Benzodiazepine efficacy and pharmacokinetics'</a> below.)</p><p class="headingAnchor" id="H4105814767"><span class="h3">In-hospital treatment</span><span class="headingEndMark"> — </span>Benzodiazepines can be administered by a variety of routes. However, if IV access is available, drugs administered by this route are more effective [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/d/html/101361.html" rel="external">"Seizures and epilepsy in children: Refractory seizures", section on 'Home rescue therapy (transmucosal antiseizure medications)'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>When IV or IO access is available</strong> – <a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">Lorazepam</a> 0.1 mg/kg intravenously (IV/intraosseous [IO]) up to a maximum of 4 mg should be administered by slow IV push over one minute and its effect assessed over the next five to ten minutes [<a href="#rid14">14</a>]. An equally effective alternative is <a class="drug drug_pediatric" data-topicid="13223" href="/d/drug information/13223.html" rel="external">diazepam</a>, although it has a shorter duration of action (&lt;20 minutes) [<a href="#rid14">14,15</a>]. The recommended dose of diazepam is 0.2 mg/kg IV or IO (maximum dose 10 mg). Treatment with benzodiazepine doses that are lower than recommended has been associated with a decreased likelihood of seizure cessation [<a href="#rid16">16</a>]. Some UpToDate experts use a higher dose of diazepam (0.3 mg/kg) based upon clinical experience, recognizing that higher doses increase the risk of respiratory depression.</p><p></p><p class="bulletIndent1">If seizures continue after five minutes, additional doses of <a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a> or <a class="drug drug_pediatric" data-topicid="13223" href="/d/drug information/13223.html" rel="external">diazepam</a> can be given  (<a class="graphic graphic_table graphicRef55368" href="/d/graphic/55368.html" rel="external">table 9</a>). The risk of respiratory depression increases after administration of more than two doses of benzodiazepines [<a href="#rid13">13,17</a>]. (See <a class="local">'Benzodiazepine efficacy and pharmacokinetics'</a> below.)</p><p></p><p class="bulletIndent1">If IV access is not rapidly obtained, then IO placement should be performed. (See  <a class="medical medical_review" href="/d/html/6321.html" rel="external">"Intraosseous infusion"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When IV and IO access are unavailable</strong> – Placement of an intravenous catheter may be difficult in some patients. When IV and IO access cannot be achieved within the first three minutes, alternative first-line agents include [<a href="#rid14">14,18</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intranasal </strong><strong>midazolam</strong> – Intranasal <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a> 0.2 mg/kg of parenteral solution per dose, divide dose between nares, maximum single dose 10 mg (mucosal atomizer device recommended), may repeat once in 10 minutes; for children ≥12 years, midazolam nasal spray 5 mg (one spray) into one nostril, may repeat in 10 minutes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intranasal </strong><strong>diazepam</strong> – Intranasal <a class="drug drug_pediatric" data-topicid="13223" href="/d/drug information/13223.html" rel="external">diazepam</a> dosing is fixed and varies by age and weight; for children age 6 to 11 years, the dose is 0.3 mg/kg  (<a class="graphic graphic_table graphicRef132522" href="/d/graphic/132522.html" rel="external">table 10</a>); for children age 12 or older, the dose is 0.2 mg/kg  (<a class="graphic graphic_table graphicRef132523" href="/d/graphic/132523.html" rel="external">table 11</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Rectal </strong><strong>diazepam</strong> – Rectal <a class="drug drug_pediatric" data-topicid="13223" href="/d/drug information/13223.html" rel="external">diazepam</a> 0.5 mg/kg, maximum 20 mg.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intramuscular </strong><strong>midazolam</strong> – IM <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a> 0.2 mg/kg once, maximum 10 mg; alternative fixed dosing is 5 mg for patients 13 to 40 kg, or 10 mg for patients &gt;40 kg.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Buccal </strong><strong>midazolam</strong> – Buccal <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a> 0.3 to 0.5 mg/kg once, maximum 10 mg.</p><p></p><p class="bulletIndent1">Among these alternatives, IM <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a> is rapidly effective. Buccal or intranasal midazolam may be more effective than rectal <a class="drug drug_pediatric" data-topicid="13223" href="/d/drug information/13223.html" rel="external">diazepam</a> but may raise the risk of aspiration [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/d/html/101361.html" rel="external">"Seizures and epilepsy in children: Refractory seizures", section on 'Home rescue therapy (transmucosal antiseizure medications)'</a>.)</p><p></p><p class="headingAnchor" id="H2276819989"><span class="h3">Benzodiazepine efficacy and pharmacokinetics</span><span class="headingEndMark"> — </span>Benzodiazepines are the first-line treatment for SE because they can rapidly control seizures [<a href="#rid4">4,8</a>]. The three most commonly used benzodiazepines to treat SE are <a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a>, <a class="drug drug_pediatric" data-topicid="13223" href="/d/drug information/13223.html" rel="external">diazepam</a>, and <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a>; for first-line IV therapy, lorazepam or diazepam are the preferred agents. Lorazepam has a longer duration of action, which may provide continued seizure control until a loading dose of a second agent can be completed. For that reason, lorazepam is preferred by most pediatric experts for in-hospital treatment of SE.</p><p>The efficacy of <a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a> and <a class="drug drug_pediatric" data-topicid="13223" href="/d/drug information/13223.html" rel="external">diazepam</a> was demonstrated in a multicenter trial in which 273 children (aged 3 months to 18 years) with convulsive SE were randomly assigned to receive lorazepam (0.1 mg/kg IV) or diazepam (0.2 mg/kg IV) upon presentation to the emergency department [<a href="#rid15">15</a>]. Half of the initial dose was repeated at 5 minutes if necessary, and <a class="drug drug_pediatric" data-topicid="13327" href="/d/drug information/13327.html" rel="external">fosphenytoin</a> was administered if seizures continued at 12 minutes. The primary outcome measure was cessation of SE by 10 minutes without recurrence in 30 minutes. SE was successfully terminated in 73 percent of those treated with lorazepam and 72 percent of those treated with diazepam (95% CI -11.4 to 9.8 percent). There was no difference in the rate of assisted ventilation for patients treated with lorazepam versus diazepam (17.6 versus 16 percent; 95% CI -9.9 to 6.8 percent). Patients treated with lorazepam were more likely to be sedated (67 versus 50 percent) and had a longer time to return of baseline mental status.</p><p>These results contrast with prior observational studies and one small randomized trial in children, which suggested that <a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a> was more effective than <a class="drug drug_pediatric" data-topicid="13223" href="/d/drug information/13223.html" rel="external">diazepam</a> in the treatment of SE and caused less respiratory depression [<a href="#rid19">19-21</a>]. Randomized trials in adults with convulsive SE have found a trend toward improved efficacy of lorazepam over diazepam and similar safety profiles [<a href="#rid22">22-24</a>].</p><p class="bulletIndent1">Additional pharmacokinetic and dosing considerations include the following:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lorazepam</strong> – The time from injection to <a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a>'s maximum effect can be as long as two minutes. The effective duration of action, as long as four to six hours, is longer than <a class="drug drug_pediatric" data-topicid="13223" href="/d/drug information/13223.html" rel="external">diazepam</a> because of its less pronounced redistribution into adipose tissue. The half-life of lorazepam (which is much longer than the period of seizure suppression) is significantly prolonged in newborns (approximately 40 hours) compared with older children or adults (10 and 13 hours, respectively) [<a href="#rid25">25-27</a>].</p><p></p><p class="bulletIndent1">As with <a class="drug drug_pediatric" data-topicid="13223" href="/d/drug information/13223.html" rel="external">diazepam</a>, rectal administration of <a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a> can be effective when IV access cannot be achieved. An intranasal formulation of lorazepam is another probably effective treatment option [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diazepam</strong> – <a class="drug drug_pediatric" data-topicid="13223" href="/d/drug information/13223.html" rel="external">Diazepam</a> has high lipid solubility, rapidly crosses the blood-brain barrier, and is highly effective in terminating seizures. An effect upon seizure activity can be seen as early as 10 to 20 seconds after administration; cerebrospinal fluid (CSF) concentrations reach one-half of their maximum value in three minutes. However, because of subsequent redistribution of the drug into adipose tissue, the duration of diazepam's acute anticonvulsant effect is typically &lt;20 minutes.</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="13223" href="/d/drug information/13223.html" rel="external">Diazepam</a> has been the drug of first choice in many settings, especially outside the emergency department, because it is stable in liquid form for long periods at room temperature. Therefore, diazepam is available in resuscitation kits in premixed form, whereas <a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a>, <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a>, and <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a> are not.</p><p></p><p class="bulletIndent1">A rectal gel formulation of <a class="drug drug_pediatric" data-topicid="13223" href="/d/drug information/13223.html" rel="external">diazepam</a> (Diastat) provides rapid delivery when IV access is problematic. Some families and caregivers will have this at home and may have already administered to the child prior to evaluation in the emergency department. A nasal spray formulation of diazepam is also available; it is approved by the US Food and Drug Administration (FDA) for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) in patients age six years and older [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Midazolam</strong> – <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">Midazolam</a> is also very effective in acutely terminating seizures, frequently in less than one minute, but it has a short half-life in the central nervous system. In addition to IV administration, it can be given by the IM, intranasal, oral, buccal, or rectal routes [<a href="#rid4">4,30,31</a>]. Thus, it is a useful agent when intravenous access cannot be established [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/d/html/101361.html" rel="external">"Seizures and epilepsy in children: Refractory seizures", section on 'Buccal therapy'</a>.)</p><p></p><p class="bulletIndent1">In a clinical trial of 893 patients (including 120 children younger than 18 years) treated in the prehospital setting, IM <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a> was shown to be at least as effective as IV <a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a> in terminating SE [<a href="#rid32">32,33</a>]. Overall, seizure remission upon arrival to the emergency department was more likely in patients treated with IM midazolam compared with IV lorazepam (73 versus 63 percent) [<a href="#rid32">32</a>]. In a secondary analysis limited to patients &lt;18 years of age, seizure remission rates were similar for midazolam versus lorazepam (68 versus 72 percent) [<a href="#rid33">33</a>]. The dose of midazolam was 5 mg for children whose weight was 13 to 40 kg and 10 mg in those over 40 kg. While lorazepam treatment was associated with a shorter median time from active treatment to cessation of convulsions (1.6 versus 3.3 minutes) among responders, this was offset in the prehospital setting by a longer median time to active treatment administration in the lorazepam group (4.8 versus 1.2 minutes) because of the need to place an IV catheter. The need for endotracheal intubation, recurrence of seizures, and other adverse event rates were similar in the two treatment groups. (See <a class="local">'Prehospital treatment'</a> above.)</p><p></p><p class="bulletIndent1">Buccal administration of <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a> was found in one study of 177 children to be more effective than rectal <a class="drug drug_pediatric" data-topicid="13223" href="/d/drug information/13223.html" rel="external">diazepam</a> in terminating seizures [<a href="#rid30">30</a>]. Fewer children required further antiseizure medication treatment in the midazolam compared with the diazepam-treated group. (See  <a class="medical medical_review" href="/d/html/101361.html" rel="external">"Seizures and epilepsy in children: Refractory seizures", section on 'Home rescue therapy (transmucosal antiseizure medications)'</a>.)</p><p></p><p class="bulletIndent1">Nasal <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a> is approved by the FDA for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) in patients age 12 years and older [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">Midazolam</a> can be given as a continuous infusion for refractory SE, but this mode of administration is not recommended as a first-line treatment for SE. (See <a class="local">'Midazolam'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clonazepam</strong> – <a class="drug drug_pediatric" data-topicid="13170" href="/d/drug information/13170.html" rel="external">Clonazepam</a> has been used to treat SE outside the United States in settings where intravenous formulations are available. It has effects similar to those of other benzodiazepines, with a rapidity of onset that is intermediate between that of <a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a> and <a class="drug drug_pediatric" data-topicid="13223" href="/d/drug information/13223.html" rel="external">diazepam</a> and a more prolonged duration of action than diazepam.</p><p></p><p class="headingAnchor" id="H1370410785"><span class="h2">Second therapy: Antiseizure medications</span><span class="headingEndMark"> — </span>If seizures continue for 10 minutes after at least two injections of <a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a> or <a class="drug drug_pediatric" data-topicid="13223" href="/d/drug information/13223.html" rel="external">diazepam</a>, a second therapy with a long-acting antiseizure medication is indicated. <a class="drug drug_pediatric" data-topicid="12910" href="/d/drug information/12910.html" rel="external">Levetiracetam</a>, <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a>/<a class="drug drug_pediatric" data-topicid="13327" href="/d/drug information/13327.html" rel="external">fosphenytoin</a>, and <a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">valproate</a> are reasonable choices in this setting [<a href="#rid9">9</a>]. The onset of action is delayed with these drugs. Therefore, it may be helpful to give an additional dose of a benzodiazepine as the antiseizure medication is being administered. (See <a class="local">'In-hospital treatment'</a> above.)</p><p>In patients with ongoing SE lasting longer than 30 minutes despite two initial doses of benzodiazepine and a second therapy antiseizure medication, preparation for a continuous infusion of <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a>, <a class="drug drug_pediatric" data-topicid="12741" href="/d/drug information/12741.html" rel="external">propofol</a>, or <a class="drug drug_pediatric" data-topicid="12693" href="/d/drug information/12693.html" rel="external">pentobarbital</a> should occur simultaneously with administration of a different second therapy antiseizure medication. At this stage, the patient will require endotracheal intubation, mechanical ventilation, transfer to a pediatric intensive care unit, and, if not already obtained, emergency neurologic consultation. (See <a class="local">'Refractory status epilepticus'</a> below.)</p><p class="headingAnchor" id="H4075300227"><span class="h3">Choosing an agent</span><span class="headingEndMark"> — </span>For children with SE that continues for 10 minutes after at least two doses of a benzodiazepine, we suggest treatment with <a class="drug drug_pediatric" data-topicid="12910" href="/d/drug information/12910.html" rel="external">levetiracetam</a> rather than another antiseizure medication.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>When IV or IO access is available</strong> – We begin treatment with <a class="drug drug_pediatric" data-topicid="12910" href="/d/drug information/12910.html" rel="external">levetiracetam</a> 60 mg/kg IV/IO (maximum single dose 4500 mg), which we prefer over <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a> because of ease of use, more rapid administration, and equivalent efficacy. (See <a class="local">'Antiseizure medication efficacy'</a> below.)</p><p></p><p class="bulletIndent1">Alternatively, <a class="drug drug_pediatric" data-topicid="13327" href="/d/drug information/13327.html" rel="external">fosphenytoin</a> can be given at a dose of 20 mg <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a> equivalents (PE)/kg IV or IO and a rate of 2 mg PE/kg per minute (maximum rate 150 mg PE/min)  (<a class="graphic graphic_table graphicRef55368" href="/d/graphic/55368.html" rel="external">table 9</a>). Although high-quality evidence is lacking, some UpToDate experts give fosphenytoin at a higher initial dose of 30 mg PE/kg IV, which in their experience is associated with excellent seizure control and tolerability. If seizures persist, an additional 5 to 10 mg PE/kg IV of fosphenytoin can be given 10 minutes after the loading dose. The maximum suggested single dose in children is 1500 mg.</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">Phenytoin</a> and <a class="drug drug_pediatric" data-topicid="13327" href="/d/drug information/13327.html" rel="external">fosphenytoin</a> may be less effective for the treatment of seizures due to toxins or drugs (eg, children with seizures caused by <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a>, cocaine, amphetamines, <a class="drug drug_pediatric" data-topicid="12554" href="/d/drug information/12554.html" rel="external">lindane</a>, or <a class="drug drug_pediatric" data-topicid="12831" href="/d/drug information/12831.html" rel="external">theophylline</a>); in such cases, an alternative such as <a class="drug drug_pediatric" data-topicid="12910" href="/d/drug information/12910.html" rel="external">levetiracetam</a>, <a class="drug drug_pediatric" data-topicid="12698" href="/d/drug information/12698.html" rel="external">phenobarbital</a>, or <a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">valproate</a> should be used.</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">Valproate</a> or <a class="drug drug_pediatric" data-topicid="12698" href="/d/drug information/12698.html" rel="external">phenobarbital</a> IV/IO may also be used as initial therapy in children who did not respond to <a class="drug drug_pediatric" data-topicid="12910" href="/d/drug information/12910.html" rel="external">levetiracetam</a> or <a class="drug drug_pediatric" data-topicid="13327" href="/d/drug information/13327.html" rel="external">fosphenytoin</a> in previous episodes of SE or in children with a hypersensitivity to <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a>. The clinician should anticipate respiratory depression and apnea when phenobarbital is given with benzodiazepines.</p><p></p><p class="bulletIndent1">In addition, <a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">valproate</a> may also be used as the initial treatment in children on chronic valproate therapy who are known to have had recent nonadherence and in whom valproate levels are suspected to be low.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When IV and IO access are not available</strong> – When either IV or IO access is delayed or unavailable, <a class="drug drug_pediatric" data-topicid="13327" href="/d/drug information/13327.html" rel="external">fosphenytoin</a> can be given by intramuscular injection.</p><p></p><p class="headingAnchor" id="H2793698149"><span class="h3">Factors influencing choice of agent</span><span class="headingEndMark"> — </span>Knowledge of the patient's previous response to antiseizure medications and current medication use may guide the approach to management. In deciding initial antiseizure therapy for SE, the following issues should be considered:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Previous response</strong> – If the child has a history of previous SE, knowing which antiseizure medication was effective in arresting the seizures is helpful. If the child did not respond to <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a> or <a class="drug drug_pediatric" data-topicid="13327" href="/d/drug information/13327.html" rel="external">fosphenytoin</a>, for example, another drug, such as <a class="drug drug_pediatric" data-topicid="12698" href="/d/drug information/12698.html" rel="external">phenobarbital</a> or <a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">valproate</a>, would be preferable.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trauma</strong> – In the setting of trauma, <a class="drug drug_pediatric" data-topicid="12910" href="/d/drug information/12910.html" rel="external">levetiracetam</a> is generally the preferred antiseizure medication for treating SE, and <a class="drug drug_pediatric" data-topicid="13327" href="/d/drug information/13327.html" rel="external">fosphenytoin</a> is also a reasonable choice. Concerns about adverse effects of <a class="drug drug_pediatric" data-topicid="12698" href="/d/drug information/12698.html" rel="external">phenobarbital</a> (sedation) and <a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">valproate</a> (thrombocytopenia and other coagulation disturbances) make them less useful in for patients with trauma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiseizure medication adherence</strong> – If the child is on long-term antiseizure medication therapy, it should be determined whether the medication has been recently missed or if prescriptions have not been refilled. Serum antiseizure medication levels obtained upon admission may not be available for many hours, and initial treatment decisions may be made without them. If, for example, <a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">valproate</a> has provided good seizure control and the child is known to have missed one or more doses, intravenous valproate, rather than <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a>, should be considered as initial treatment.</p><p></p><p class="bulletIndent1">Low antiseizure medication levels may contribute to SE in up to one-third of patients [<a href="#rid3">3</a>]. In one series of 51 children with SE, at least one or all antiseizure medication levels were therapeutic in 82 and 66 percent, respectively [<a href="#rid35">35</a>]. In addition to nonadherence, there are a number of other clinical scenarios that may lead to an unexpectedly low serum level of an antiseizure medication. These include medical conditions such as vomiting or malabsorption and administration of concomitant medications that may increase clearance of a particular antiseizure medication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paradoxical effects of antiseizure medications</strong> – Elevated levels of certain antiseizure medications, including <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a>, <a class="drug drug_pediatric" data-topicid="13113" href="/d/drug information/13113.html" rel="external">carbamazepine</a>, <a class="drug drug_pediatric" data-topicid="13330" href="/d/drug information/13330.html" rel="external">gabapentin</a>, <a class="drug drug_pediatric" data-topicid="12841" href="/d/drug information/12841.html" rel="external">tiagabine</a>, and <a class="drug drug_pediatric" data-topicid="13101" href="/d/drug information/13101.html" rel="external">vigabatrin</a>, can paradoxically trigger generalized convulsive SE, particularly the myoclonic type, as well as nonconvulsive (absence) SE. The underlying mechanisms are poorly understood [<a href="#rid36">36</a>]. When suspected, paradoxical seizures caused by phenytoin or carbamazepine should be managed with benzodiazepines and <a class="drug drug_pediatric" data-topicid="12698" href="/d/drug information/12698.html" rel="external">phenobarbital</a>. (See  <a class="medical medical_review" href="/d/html/332.html" rel="external">"Carbamazepine poisoning"</a> and  <a class="medical medical_review" href="/d/html/312.html" rel="external">"Phenytoin poisoning"</a>.)</p><p></p><p class="bulletIndent1">Even benzodiazepines can rarely worsen seizures and precipitate tonic SE, particularly in children with Lennox-Gastaut syndrome [<a href="#rid37">37</a>], although this should not alter the standard initial approach to therapy.</p><p></p><p class="bulletIndent1">Some antiseizure medications commonly used to treat SE may worsen seizures caused by illicit drugs. As an example, <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a> could worsen the toxicity of <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a> or cocaine, because both block sodium channels [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1">Selected antiseizure medications may also precipitate or worsen other types of seizures [<a href="#rid36">36</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13113" href="/d/drug information/13113.html" rel="external">Carbamazepine</a>, <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a>, and <a class="drug drug_pediatric" data-topicid="12542" href="/d/drug information/12542.html" rel="external">lamotrigine</a> may worsen myoclonic seizures.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At high serum levels, <a class="drug drug_pediatric" data-topicid="13113" href="/d/drug information/13113.html" rel="external">carbamazepine</a> and <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a> may worsen focal seizures with impairment of consciousness (previously called complex partial seizures) and increase generalized tonic-clonic seizures.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13113" href="/d/drug information/13113.html" rel="external">Carbamazepine</a> is known to precipitate drop attacks, often with atypical absence seizures.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13113" href="/d/drug information/13113.html" rel="external">Carbamazepine</a> and <a class="drug drug_pediatric" data-topicid="12542" href="/d/drug information/12542.html" rel="external">lamotrigine</a> may worsen seizures in patients with Dravet syndrome. (See  <a class="medical medical_review" href="/d/html/108722.html" rel="external">"Dravet syndrome: Management and prognosis", section on 'Drugs to avoid'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Change in antiseizure medications</strong> – Seizures may be worsened or precipitated even when antiseizure medication blood levels are in the therapeutic range [<a href="#rid39">39</a>]. If a new antiseizure medication has been added or the dose has been increased in the previous months, the drug may be causing seizures and should not be used in an attempt to control SE.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonprescription and illicit drugs</strong> – Nonprescription medications, including over-the-counter drugs such as antihistamines or other agents with anticholinergic effects, illicit substances, and, rarely, herbal preparations, can precipitate seizures. Specific questioning may uncover the use of these substances, especially illicit drug use. Since this information is typically unavailable early in the course of managing SE, we obtain a urine drug screen as part of the initial evaluation in at-risk patients (eg, adolescents and older school children, and younger children if there is suspicion for illicit drug exposure). (See <a class="local">'Initial studies'</a> above.)</p><p></p><p class="headingAnchor" id="H3373635298"><span class="h3">Antiseizure medication efficacy</span><span class="headingEndMark"> — </span>Mounting evidence from randomized controlled trials and observational studies suggests that <a class="drug drug_pediatric" data-topicid="12910" href="/d/drug information/12910.html" rel="external">levetiracetam</a>, <a class="drug drug_pediatric" data-topicid="13327" href="/d/drug information/13327.html" rel="external">fosphenytoin</a>/<a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a>, and <a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">valproate</a> have similar efficacy for convulsive SE in children [<a href="#rid40">40,41</a>]. Phenytoin and fosphenytoin may be less effective for the treatment of seizures due to toxins or drugs and may intensify seizures caused by cocaine, other local anesthetics, <a class="drug drug_pediatric" data-topicid="12831" href="/d/drug information/12831.html" rel="external">theophylline</a>, or <a class="drug drug_pediatric" data-topicid="12554" href="/d/drug information/12554.html" rel="external">lindane</a> [<a href="#rid42">42-44</a>]. In such cases, levetiracetam, valproate, or <a class="drug drug_pediatric" data-topicid="12698" href="/d/drug information/12698.html" rel="external">phenobarbital</a> should be used.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comparative efficacy</strong> – Among the antiseizure medications that can be loaded intravenously, the Established Status Epilepticus Treatment Trial (ESETT) found that <a class="drug drug_pediatric" data-topicid="13327" href="/d/drug information/13327.html" rel="external">fosphenytoin</a>, <a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">valproate</a>, and <a class="drug drug_pediatric" data-topicid="12910" href="/d/drug information/12910.html" rel="external">levetiracetam</a> are equally effective and have similar rates of adverse effects [<a href="#rid45">45</a>]. The trial enrolled 384 children (aged 2 to 17 years) and adults with convulsive SE refractory to benzodiazepines. The patients were randomly assigned to receive levetiracetam (n = 145), fosphenytoin (n = 118), or valproate (n = 121). The trial was stopped early when an interim analysis met criteria for futility. The composite outcome (cessation of SE and improvement in the level of consciousness at 60 minutes) was achieved in 47 percent (95% CI 39-55) of the levetiracetam group, 45 percent (95% CI 36-54) of the fosphenytoin group, and 46 percent of patients (95% CI 38-55) in the valproate group. Although not statistically significant, there were more episodes of hypotension and intubation in the fosphenytoin group and more deaths in the levetiracetam group compared with the other groups. Limitations to the ESETT include a substantial rate (approximately 50 percent) of unblinding of investigators and clinicians to permit choosing a second antiseizure medication for ongoing seizures, inadvertent enrollment of patients without SE, including patients with psychogenic nonepileptic seizures (approximately 10 percent of the study population), and absence of confirmatory electroencephalography.</p><p></p><p class="bulletIndent1">In an extension of ESETT, which enrolled an additional 78 children with SE, there was no difference in the efficacy of <a class="drug drug_pediatric" data-topicid="12910" href="/d/drug information/12910.html" rel="external">levetiracetam</a>, <a class="drug drug_pediatric" data-topicid="13327" href="/d/drug information/13327.html" rel="external">fosphenytoin</a>, or <a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">valproate</a> by age group comparing children, younger adults (ages 18 to 65 years), and older adults (age &gt;65 years) [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1">Data from two open-label trials suggest that <a class="drug drug_pediatric" data-topicid="12910" href="/d/drug information/12910.html" rel="external">levetiracetam</a> is equivalent but not superior to <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a> for the treatment of convulsive SE. The ConSEPT trial randomly assigned 233 children (aged 3 months to 16 years) presenting to emergency departments with convulsive SE who failed initial benzodiazepine treatment to phenytoin 20 mg/kg infusion (IV or IO) over 20 minutes or levetiracetam 40 mg/kg infusion (IV or IO) over 5 minutes [<a href="#rid46">46</a>]. At five minutes after the end of infusion, the proportion of patients with clinical cessation of seizure activity in the phenytoin and levetiracetam groups was similar (60 versus 50 percent, respectively; risk difference -9.2 percent, 95% CI -21.9 to 3.5), and there was no difference between groups in any of the other primary or secondary outcomes. Similarly, the EcLiPSE trial evaluated 286 children (aged 6 months to 18 years) with convulsive SE requiring second-therapy treatment who were randomly assigned to levetiracetam 40 mg/kg IV over 5 minutes or phenytoin 20 mg/kg IV over at least 20 minutes [<a href="#rid47">47</a>]. There was no significant difference between groups in any of the prespecified outcomes. The proportion of patients with cessation of convulsive SE was similar for the levetiracetam and phenytoin groups (70 and 64 percent), as was the primary outcome of median time to cessation of SE with levetiracetam and phenytoin (35 and 45 minutes, hazard ratio 1.20, 95% CI 0.91-1.60). In both trials, levetiracetam and phenytoin had similar safety profiles [<a href="#rid46">46,47</a>].</p><p></p><p class="bulletIndent1">In one of the larger retrospective series, 78 children (median age 31 months) with SE refractory to initial benzodiazepines and two second-therapy antiseizure medications (<a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a> and <a class="drug drug_pediatric" data-topicid="12698" href="/d/drug information/12698.html" rel="external">phenobarbital</a>) were treated with either <a class="drug drug_pediatric" data-topicid="12910" href="/d/drug information/12910.html" rel="external">levetiracetam</a> (20 mg/kg IV at 5 mg/kg per minute, maximum 3 grams) or <a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">valproate</a> (20 mg/kg IV), prior to continuous infusional therapy [<a href="#rid48">48</a>]. The rate of seizure control was similar for levetiracetam and valproate (78 versus 63 percent, p = 0.12). An adjusted analysis was not presented. No specific adverse effects were ascribed to levetiracetam; valproate caused reversible liver enzyme elevation in four patients (13 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Levetiracetam</strong> – The ConSEPT and EcLiPSE trials both used <a class="drug drug_pediatric" data-topicid="12910" href="/d/drug information/12910.html" rel="external">levetiracetam</a> 40 mg/kg dosing for convulsive SE [<a href="#rid46">46,47</a>], while most earlier and smaller reports used a dose of 20 to 30 mg/kg [<a href="#rid48">48-52</a>]; single doses of up to 60 mg/kg had been endorsed by at least two guideline panels [<a href="#rid8">8,9</a>]. Levetiracetam is available in intravenous as well as oral formulations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fosphenytoin</strong><strong> and </strong><strong>phenytoin</strong> – <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">Phenytoin</a> is a long-acting drug that has been widely used to treat acute and chronic seizures in children [<a href="#rid4">4</a>]. Its principal advantage is in preventing recurrence of SE for extended periods of time.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fosphenytoin</strong> – <a class="drug drug_pediatric" data-topicid="13327" href="/d/drug information/13327.html" rel="external">Fosphenytoin</a> is a pro-drug of <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a> that is preferred over phenytoin in the treatment of SE because it has a better safety profile and can be infused more rapidly than phenytoin. Fosphenytoin is highly water soluble at neutral pH and therefore unlikely to precipitate during intravenous administration. Compared with phenytoin, the drug has fewer side effects, including a reduced risk of local irritation at the site of infusion; therefore, fosphenytoin can be infused much more rapidly. Hypotension and cardiac arrhythmias remain a risk, so cardiac monitoring is still required.</p><p></p><p class="bulletIndent2">Little information is available on the pharmacokinetics of <a class="drug drug_pediatric" data-topicid="13327" href="/d/drug information/13327.html" rel="external">fosphenytoin</a> in infants and children. Subtherapeutic free <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a> levels may occur rarely in children after fosphenytoin infusion [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent2">Since <a class="drug drug_pediatric" data-topicid="13327" href="/d/drug information/13327.html" rel="external">fosphenytoin</a> is converted on a 1:1 molar basis to <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a>, the dosing of fosphenytoin in terms of moles is identical. However, the molecular weight of fosphenytoin is greater than that of phenytoin; hence, a greater weight of fosphenytoin must be given in order to yield the same concentration of phenytoin. To eliminate potential confusion, fosphenytoin is prescribed as milligrams of phenytoin equivalent (PE); as an example, 20 mg PE/kg load, at a rate of 2 mg PE/kg per minute.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Phenytoin</strong> – If <a class="drug drug_pediatric" data-topicid="13327" href="/d/drug information/13327.html" rel="external">fosphenytoin</a> is unavailable, <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a> can be given in an initial dose of 20 mg/kg IV at a rate of 1 mg/kg per minute (maximum rate 50 mg/min). Phenytoin is not water soluble; in order to have a liquid preparation, it is dissolved in propylene glycol at a very high pH. This contributes in large part to the phenytoin's side effects of hypotension and cardiac arrhythmias. Thus, heart rate and blood pressure should be monitored during the initial infusion. However, these complications are less common in children than adults and can be minimized by an infusion rate that does not exceed 1 mg/kg per minute (maximum 50 mg per minute) [<a href="#rid4">4</a>]. Phenytoin must not be infused along with a dextrose containing IV fluid, as it may form a precipitate.</p><p></p><p class="bulletIndent2">The risks of local pain and injury, including venous thrombosis and the purple glove syndrome, also increase with more rapid rates of infusion. The purple glove syndrome is characterized by edema, discoloration, and pain in the extremity distal to the site of <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a> infusion. Severe cases can lead to skin necrosis and limb ischemia, sometimes requiring amputation. More common in older adults, a few cases have been reported in children, usually late in the first decade, and adolescents. Venous extravasation must be avoided because the high pH and osmolality of this drug cause tissue inflammation and necrosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Valproate</strong> – <a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">Valproate</a> can be used if seizures continue for 10 minutes after at least two doses of a benzodiazepine. Valproate is given in a loading dose of 20 to 40 mg/kg IV (diluted 1:1 with normal <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> or <a class="drug drug_pediatric" data-topicid="13222" href="/d/drug information/13222.html" rel="external">5 percent dextrose in water</a>) over 5 to 10 minutes (maximum 3000 mg per dose) and may be repeated after 10 to 15 minutes [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">Valproate</a> usually is well tolerated, even in clinically unstable patients, and is less sedating than barbiturates [<a href="#rid4">4,55</a>]. Severe hypotension was reported in an 11-year-old girl following intravenous administration [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phenobarbital</strong> – <a class="drug drug_pediatric" data-topicid="12698" href="/d/drug information/12698.html" rel="external">Phenobarbital</a> slowly infused IV (maximum infusion rate 2 mg/kg per minute with a ceiling of 50 mg/min) in an initial dose of 20 mg/kg, and followed by repeated increments of approximately 8 to 10 mg/kg every 30 minutes, can achieve high levels and seizure control, usually without significant hypotension or respiratory depression.</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12698" href="/d/drug information/12698.html" rel="external">Phenobarbital</a> is a long-acting antiseizure medication that has been used for many years to treat seizures. Side effects of IV administration include sedation and respiratory depression, especially when it is preceded by a benzodiazepine. As a result, phenobarbital is considered a second-line long-acting agent after <a class="drug drug_pediatric" data-topicid="12910" href="/d/drug information/12910.html" rel="external">levetiracetam</a>, <a class="drug drug_pediatric" data-topicid="13327" href="/d/drug information/13327.html" rel="external">fosphenytoin</a> or <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a>, and <a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">valproate</a>, and usually is used only when these agents are not effective. Respiratory and cardiac monitoring should be performed because endotracheal intubation and mechanical ventilation may be needed. The risk of prolonged sedation with phenobarbital is greater than with the other anticonvulsants because its half-life is 87 to 100 hours, and often longer in newborns [<a href="#rid57">57</a>].</p><p></p><p class="headingAnchor" id="H18020055"><span class="h1">REFRACTORY STATUS EPILEPTICUS</span></p><p class="headingAnchor" id="H575480232"><span class="h2">Medications for refractory status epilepticus</span><span class="headingEndMark"> — </span>If convulsive SE persists for 30 minutes after initial measures are instituted (immediate benzodiazepine treatment followed by second therapy with an antiseizure medication), further pharmacologic therapy (third therapy) is required  (<a class="graphic graphic_algorithm graphicRef131955" href="/d/graphic/131955.html" rel="external">algorithm 1</a>), usually with continuous infusion of <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a> (preferred) or <a class="drug drug_pediatric" data-topicid="12693" href="/d/drug information/12693.html" rel="external">pentobarbital</a> [<a href="#rid58">58</a>].</p><p>Among these, <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a> is the most frequent first-choice sedative-anesthetic agent, followed by <a class="drug drug_pediatric" data-topicid="12693" href="/d/drug information/12693.html" rel="external">pentobarbital</a>. Although <a class="drug drug_pediatric" data-topicid="12741" href="/d/drug information/12741.html" rel="external">propofol</a> has been used to treat SE, data are limited, and significant associated complications have been reported. Propofol should not be used in children on the ketogenic diet; a report of a fatality in a 10-year-old boy illustrates the incompatibility of these treatments, which both involve fatty acid metabolism [<a href="#rid59">59</a>].</p><p>The patient's hemodynamic status will bear on the choice, because <a class="drug drug_pediatric" data-topicid="12693" href="/d/drug information/12693.html" rel="external">pentobarbital</a> and <a class="drug drug_pediatric" data-topicid="12741" href="/d/drug information/12741.html" rel="external">propofol</a> may exacerbate cardiovascular complications including hypotension. Dosing of these agents and important contraindications are discussed below. (See <a class="local">'Specific agents'</a> below.)</p><p>At this stage, the patient will require endotracheal intubation, mechanical ventilation, emergency neurologic consultation if not already obtained, and transfer to a pediatric intensive care unit with continuous EEG capability. The clinician should also anticipate the need to treat iatrogenic hypotension. Rapid infusion of isotonic crystalloid (eg, 20 mL/kg of normal <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> or Ringer lactate) followed by a continuous infusion of a vasopressor such as <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a> or <a class="drug drug_pediatric" data-topicid="12650" href="/d/drug information/12650.html" rel="external">norepinephrine</a> are frequently necessary to maintain adequate tissue perfusion and blood pressure.</p><p class="headingAnchor" id="H673923498"><span class="h2">Continuous EEG monitoring</span><span class="headingEndMark"> — </span>Continuous EEG (cEEG) monitoring is critical during the treatment of refractory SE. The longer convulsive SE continues, the less convulsive it appears clinically, and continuous electroencephalogram (cEEG) monitoring should be instituted. Once infusion of <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a> or <a class="drug drug_pediatric" data-topicid="12693" href="/d/drug information/12693.html" rel="external">pentobarbital</a> has begun, cEEG monitoring is necessary to confirm that seizures have been treated adequately; to guide use of antiseizure medications and assess the level of suppression achieved; and to monitor for relapse of seizures and SE, especially when infusions are tapered.</p><p class="headingAnchor" id="H1086195516"><span class="h2">Goals of therapy</span><span class="headingEndMark"> — </span>The primary goal of therapy is to stop both clinical and electrographic seizures. There is no conclusive evidence that a burst-suppression EEG pattern is necessary, and more suppression equates to more sedation and a longer intensive care unit course of treatment. The cEEG must be followed closely, as recurrent seizures often appear on the EEG before they are evident clinically. However, the optimal electroclinical endpoint of treatment has not been studied rigorously.</p><p class="headingAnchor" id="H1740906693"><span class="h2">Specific agents</span></p><p class="headingAnchor" id="H2683536277"><span class="h3">Midazolam</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">Midazolam</a> can be given as a continuous intravenous (IV) infusion for refractory SE and is usually associated with minimal cardiovascular side effects [<a href="#rid60">60-64</a>]. Midazolam is given as an initial bolus infusion of 0.2 mg/kg IV followed by a continuous infusion of 0.05 to 2 mg/kg per hour; for breakthrough seizures, additional 0.1 to 0.2 mg/kg boluses can be given and the continuous infusion rate increased by 0.05 to 0.1 mg/kg per hour every three to four hours [<a href="#rid8">8</a>].</p><p>Hypotension may be less common than with <a class="drug drug_pediatric" data-topicid="12693" href="/d/drug information/12693.html" rel="external">pentobarbital</a> but commonly occurs at higher doses of <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a>. The short half-life of midazolam (one to four hours) can increase markedly after days of use. Tachyphylaxis is common, and the anticonvulsant effects of midazolam can cease rapidly when it is stopped. Withdrawal seizures and recurrent SE are therefore an important concern.</p><p>In a prospective multicenter study of 54 children with refractory SE who underwent continuous infusion of an anesthetic drug, 78 percent received <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a> as the first-choice agent [<a href="#rid58">58</a>]. <a class="drug drug_pediatric" data-topicid="12693" href="/d/drug information/12693.html" rel="external">Pentobarbital</a> was the most commonly used therapy after midazolam failure (82 percent). Seizure termination was achieved in 30 out of 42 patients (71 percent) who received first-line midazolam, and an additional eight patients achieved seizure termination with one more drug (mostly pentobarbital). The median length of intensive care unit stay was 10 days in the entire cohort, and 28 percent of patients required vasopressor support.</p><p class="headingAnchor" id="H27"><span class="h3">Pentobarbital</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12693" href="/d/drug information/12693.html" rel="external">Pentobarbital</a> is given as an initial bolus infusion of 5 to 15 mg/kg IV followed by a continuous infusion of 0.5 to 5 mg/kg per hour [<a href="#rid4">4</a>].</p><p>Significant side effects include respiratory depression, hypotension, myocardial depression, and reduced cardiac output. Thus, intubation and mechanical ventilation with intravascular pressure monitoring are required prior to treatment, and inotropic agents frequently are needed. Other important potential complications include pulmonary edema, ileus, and prolonged sedation.</p><p class="headingAnchor" id="H29"><span class="h3">Propofol</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12741" href="/d/drug information/12741.html" rel="external">Propofol</a> is rarely used for the treatment of SE in children because doses and duration of therapy necessary to control refractory seizures are associated with life-threatening propofol infusion syndrome characterized by one or more of severe metabolic acidosis, rhabdomyolysis, and ECG changes, with or without cardiovascular collapse, hyperlipidemia, renal failure, elevated liver enzymes, or elevated lactate [<a href="#rid65">65-67</a>]. Risk factors for the propofol infusion syndrome include high infusion doses (&gt;67 mcg/kg per minute or &gt;4 mg/kg per hour), prolonged administration (&gt;48 hours), and administration to children on the ketogenic diet [<a href="#rid59">59</a>]. Others have found that propofol may be used without severe adverse effects if the dose is not titrated above 5 mg/kg per hour and with continuous monitoring and stopping the infusion if side effects appear [<a href="#rid68">68</a>]. However, these doses may be insufficient to control refractory SE.</p><p class="headingAnchor" id="H18021443"><span class="h3">Other therapies</span><span class="headingEndMark"> — </span>In addition to <a class="drug drug_pediatric" data-topicid="12910" href="/d/drug information/12910.html" rel="external">levetiracetam</a>, observational data suggest that other antiseizure medications, including <a class="drug drug_pediatric" data-topicid="83877" href="/d/drug information/83877.html" rel="external">lacosamide</a>, and <a class="drug drug_pediatric" data-topicid="12851" href="/d/drug information/12851.html" rel="external">topiramate</a>, may play a role in the management of SE, particularly in the refractory setting. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lacosamide</strong> – <a class="drug drug_pediatric" data-topicid="83877" href="/d/drug information/83877.html" rel="external">Lacosamide</a> is also available in both oral and intravenous formulations, and there are an increasing number of case reports and case series describing its utility in adults with refractory SE [<a href="#rid69">69-71</a>]. The bolus dose most often used in adults is 200 to 400 mg IV infused over three to five minutes [<a href="#rid69">69</a>]. Published data in children are limited [<a href="#rid72">72-75</a>]. One small, retrospective case series suggests that infusions of 50 mg or 100 mg in children and young adults can be effective in cases of refractory tonic SE [<a href="#rid73">73</a>]. Another cases series of nine patients treated with a mean initial loading dose of 8.7 mg/kg reported no serious adverse effects and one episode of bradycardia [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topiramate</strong> – <a class="drug drug_pediatric" data-topicid="12851" href="/d/drug information/12851.html" rel="external">Topiramate</a> has a broad spectrum of efficacy against many seizure types. Case reports and small case series report that it may be efficacious in refractory SE [<a href="#rid76">76-78</a>]. Some have used low initial doses [<a href="#rid76">76,77</a>], others a higher loading dose [<a href="#rid78">78</a>]. There is no formulation for parenteral administration. Further prospective study is needed to define the role of topiramate in SE.</p><p></p><p>Other emerging therapies include <a class="drug drug_pediatric" data-topicid="13398" href="/d/drug information/13398.html" rel="external">ketamine</a> [<a href="#rid79">79-81</a>] and the ketogenic diet [<a href="#rid82">82-84</a>]. (See  <a class="medical medical_review" href="/d/html/14438.html" rel="external">"Ketogenic dietary therapies for the treatment of epilepsy", section on 'Super-refractory status epilepticus'</a>.)</p><p class="headingAnchor" id="H197480955"><span class="h2">Duration of continuous infusions</span><span class="headingEndMark"> — </span>Continuous infusions of sedative-anesthetic agents for refractory SE require management by pediatric neurology and critical care specialists in a pediatric intensive care unit.</p><p>Therapy with <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a> (preferred) or <a class="drug drug_pediatric" data-topicid="12693" href="/d/drug information/12693.html" rel="external">pentobarbital</a> is titrated to induce cessation of clinical and electrographic seizures, as confirmed by cEEG monitoring. The dose is then slowly reduced while monitoring to ensure that seizures do not reappear. If seizures recur, the dose is increased to achieve seizure suppression again for a period of time, followed by attempts to reduce the infusion while maintaining control of seizures.</p><p class="headingAnchor" id="H960927390"><span class="h1">POSTICTAL RECOVERY AND FURTHER EVALUATION</span></p><p class="headingAnchor" id="H3901533851"><span class="h2">Pace of recovery</span><span class="headingEndMark"> — </span>Most children begin to recover responsiveness within 20 to 30 minutes after generalized convulsions, although there is a broad range of duration. Close monitoring during the immediate postictal phase is critical, particularly for respiratory status. This is a vulnerable time, as some patients may not be able to maintain their airway without basic airway maneuvers such as a jaw thrust or chin lift or insertion of airway adjuncts such as a nasopharyngeal or oral airway; monitoring the end-tidal CO<sub>2</sub> can help assess adequacy of ventilation. (See  <a class="medical medical_review" href="/d/html/6383.html" rel="external">"Basic airway management in children"</a>.)</p><p>The two most common reasons for delayed postictal recovery are sedation from medications and ongoing nonconvulsive seizures [<a href="#rid85">85</a>], and these two causes can be impossible to distinguish clinically. Note that benzodiazepine reversal with <a class="drug drug_pediatric" data-topicid="13307" href="/d/drug information/13307.html" rel="external">flumazenil</a> is contraindicated in this setting, as reversal can precipitate seizures.</p><p>All children who do not return to a normal level of consciousness within a few hours after initial treatment of SE should therefore undergo an emergency EEG; continuous EEG monitoring and escalation of treatment is indicated if the routine EEG shows nonconvulsive SE. (See <a class="local">'Electroencephalography'</a> below and  <a class="medical medical_review" href="/d/html/14103.html" rel="external">"Nonconvulsive status epilepticus: Classification, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/129547.html" rel="external">"Nonconvulsive status epilepticus: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H2885509429"><span class="h2">History and physical examination</span><span class="headingEndMark"> — </span>During the postictal recovery period. it is important to perform a detailed history, physical examination, and a full neurologic examination that looks for asymmetric or focal findings or signs of increased intracranial pressure that may suggest clues to the underlying etiology.</p><p>The causes of SE and the evaluation and diagnosis of seizures in children are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6222.html" rel="external">"Clinical features and complications of status epilepticus in children", section on 'Causes'</a> and  <a class="medical medical_review" href="/d/html/6218.html" rel="external">"Seizures and epilepsy in children: Clinical and laboratory diagnosis"</a>.)</p><p class="headingAnchor" id="H1868484396"><span class="h2">Electroencephalography</span><span class="headingEndMark"> — </span>For patients with SE as the first presentation of seizures or epilepsy, an EEG should be done to evaluate background activity as soon as possible after the seizure stops, ideally within one to two hours. An EEG may not be necessary for patients with known epilepsy who are recovering normally from SE if the clinicians are confident the clinical seizures have stopped and there is no other independent reason that the child would benefit from ongoing EEG monitoring. Useful clues to the cessation of a clinical seizure are eye closure and resumption of a normal breathing pattern. An EEG may be useful if the eyes remain open or there is any lingering doubt as to the continuation of subclinical seizures.</p><p>EEG monitoring may be useful if the patient does not return to normal mentation in an appropriate time after cessation of SE. The clinician may also elect to perform cEEG in patients with acute symptomatic causes where the etiology could potentially cause further neurologic injury (eg, meningitis, trauma, etc.).</p><p>The EEG background usually remains abnormally slow for hours or even days after generalized convulsive or prolonged partial SE, but it is normal in psychogenic nonepileptic seizures unless large doses of sedating antiseizure medications have been given. If the patient has not regained a relatively normal mental state within a few hours after SE has stopped, an EEG should be performed to evaluate the possibility of subclinical electrographic seizures [<a href="#rid86">86</a>].</p><p>Studies of critically ill children who undergo continuous EEG monitoring indicate that electrographic seizures are present in approximately 30 to 40 percent of recordings, often without clinical accompaniment [<a href="#rid87">87-89</a>]. Similar findings have been reported in critically ill adults. The benefit of continuous EEG monitoring in unselected patients is unclear. However, the possibility of nonconvulsive seizures should be considered in such patients when the degree of coma is not adequately explained by their underlying condition.</p><p class="headingAnchor" id="H1240133547"><span class="h2">Neuroimaging</span><span class="headingEndMark"> — </span>A neuroimaging study is essential when SE is the first presentation of epilepsy as well as in children whose recovery from SE does not follow the expected course [<a href="#rid90">90,91</a>]. Computed tomography may be performed in the emergency department setting, but magnetic resonance imaging has superior yield for determining the underlying etiology. (See  <a class="medical medical_review" href="/d/html/6222.html" rel="external">"Clinical features and complications of status epilepticus in children", section on 'Causes'</a>.)</p><p class="headingAnchor" id="H2354071895"><span class="h2">Additional studies</span><span class="headingEndMark"> — </span>Additional laboratory studies may be warranted for selected patients with SE based upon the most likely etiology as discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Septic shock. (See  <a class="medical medical_review" href="/d/html/6395.html" rel="external">"Sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis", section on 'Laboratory studies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Meningitis or encephalitis. (See  <a class="medical medical_review" href="/d/html/5968.html" rel="external">"Bacterial meningitis in children older than one month: Clinical features and diagnosis", section on 'Evaluation'</a> and  <a class="medical medical_review" href="/d/html/5983.html" rel="external">"Viral meningitis in children: Clinical features and diagnosis", section on 'Evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic studies for inborn errors of metabolism in infants younger than six months of age or children with other suggestive indicators. (See  <a class="medical medical_review" href="/d/html/6218.html" rel="external">"Seizures and epilepsy in children: Clinical and laboratory diagnosis", section on 'Laboratory and genetic testing in undiagnosed epilepsy'</a>.)</p><p></p><p class="headingAnchor" id="H2511174438"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113981.html" rel="external">"Society guideline links: Seizures and epilepsy in children"</a>.)</p><p class="headingAnchor" id="H33"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Convulsive status epilepticus (SE) is a clinical diagnosis, confirmed in most cases by the presence of sustained and rhythmic generalized tonic and clonic motor activity lasting for longer than five minutes or repetitive convulsive seizures without a return to baseline consciousness between seizures. Although the diagnosis of convulsive SE is usually obvious, a detailed neurologic examination is important in making the diagnosis of more subtle or focal forms of SE. (See <a class="local">'Definition and differential diagnosis'</a> above and <a class="local">'Urgent focused evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive care</strong> – The initial assessment, stabilization, and treatment of a child presenting with SE should proceed in quick succession and include the following  (<a class="graphic graphic_algorithm graphicRef131955" href="/d/graphic/131955.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A brief physical examination to assess respiratory and circulatory status, with immediate interventions as necessary, and a rapid neurologic examination to confirm the presence of SE. (See <a class="local">'Rapid recognition of status epilepticus'</a> above and <a class="local">'Immediate supportive care'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Maintenance of an adequate airway, breathing, and circulation, along with continuous pulse oximetry and cardiac monitoring performed simultaneously with initiation of emergency antiseizure treatment. (See <a class="local">'Immediate supportive care'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Laboratory studies  (<a class="graphic graphic_table graphicRef69291" href="/d/graphic/69291.html" rel="external">table 12</a>) including (see <a class="local">'Initial studies'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Plasma glucose and a rapid "finger-stick" or point-of-care glucose</p><p class="bulletIndent3"><span class="glyph">-</span>Serum electrolytes and calcium</p><p class="bulletIndent3"><span class="glyph">-</span>Serum antiseizure medication levels, if applicable</p><p class="bulletIndent3"><span class="glyph">-</span>If substance use or poisoning is suspected, urine and blood toxicology</p><p class="bulletIndent3"><span class="glyph">-</span>In postmenarchal females, qualitative pregnancy test (urine or blood)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinically obvious SE should be treated immediately, without waiting for an EEG. When there is uncertainty regarding the presence of SE, an urgent EEG should be obtained. In the emergency department, this can be a limited study. (See <a class="local">'Approach'</a> above and <a class="local">'Electroencephalography'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>–<strong> </strong>The management of convulsive SE in children is summarized in the algorithm  (<a class="graphic graphic_algorithm graphicRef131955" href="/d/graphic/131955.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>First therapy</strong> – For children presenting with convulsive SE, we recommend immediate treatment with a benzodiazepine (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). For children with intravenous (IV) access, the preferred benzodiazepines are either <a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a> 0.1 mg/kg IV (maximum 4 mg per dose) or <a class="drug drug_pediatric" data-topicid="13223" href="/d/drug information/13223.html" rel="external">diazepam</a> 0.2 mg/kg IV (maximum 10 mg per dose), administered by slow IV push over one minute. The dose can be repeated in 5 to 10 minutes if seizures persist. (See <a class="local">'First therapy: Benzodiazepines'</a> above and <a class="local">'Benzodiazepine efficacy and pharmacokinetics'</a> above.)</p><p></p><p class="bulletIndent2">In the prehospital setting, or if IV access is delayed or impossible, an alternative to IV <a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a> or IV <a class="drug drug_pediatric" data-topicid="13223" href="/d/drug information/13223.html" rel="external">diazepam</a> for initial therapy is intramuscular (IM) <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a> at a dose of 0.1 to 0.2 mg/kg up to a maximum of 10 mg. Other options if IV access cannot be established are intranasal midazolam, intranasal diazepam, rectal diazepam (0.5 mg/kg, maximum 20 mg), and buccal midazolam (0.2 mg/kg, maximum 10 mg). (See <a class="local">'Prehospital treatment'</a> above and <a class="local">'In-hospital treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Second therapy</strong> – For children with SE that continues for 10 minutes after at least two doses of a benzodiazepine, additional antiseizure medication is required; for such patients, we suggest treatment with <a class="drug drug_pediatric" data-topicid="12910" href="/d/drug information/12910.html" rel="external">levetiracetam</a> rather than another antiseizure medication (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Levetiracetam is given at a dose of 60 mg/kg IV. <a class="drug drug_pediatric" data-topicid="13327" href="/d/drug information/13327.html" rel="external">Fosphenytoin</a> is our preferred alternative to levetiracetam except for toxin-induced seizures. <a class="drug drug_pediatric" data-topicid="12698" href="/d/drug information/12698.html" rel="external">Phenobarbital</a> and <a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">valproate</a> are additional antiseizure medications for second therapy in this setting. (See <a class="local">'Second therapy: Antiseizure medications'</a> above and <a class="local">'Choosing an agent'</a> above and <a class="local">'Antiseizure medication efficacy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Refractory status epilepticus</strong> – If SE persists for 30 minutes after initial measures are instituted, further pharmacologic therapy usually consists of continuous infusion of <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a> (preferred) or, if hemodynamic status permits, <a class="drug drug_pediatric" data-topicid="12693" href="/d/drug information/12693.html" rel="external">pentobarbital</a>. At this stage, the patient will require intubation, mechanical ventilation, neurologic consultation if not already obtained, and transfer to a pediatric intensive care unit with continuous EEG capability. (See <a class="local">'Refractory status epilepticus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postictal recovery </strong>– Most children begin to recover responsiveness within 20 to 30 minutes after generalized convulsions, although there is a broad range of duration. Close monitoring during this period is critical. An emergency EEG should be obtained in all children who do not return to a relatively normal mental state within a few hours after SE has stopped to evaluate for the possibility of subclinical seizures. (See <a class="local">'Postictal recovery and further evaluation'</a> above.)</p><p></p><p class="bulletIndent1">During the postictal recovery period, it is important to perform a detailed history, physical examination, and a full neurologic examination that looks for asymmetric or focal findings or signs of increased intracranial pressure that may suggest clues to the underlying etiology. The causes of SE and the evaluation and diagnosis of seizures in children are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6222.html" rel="external">"Clinical features and complications of status epilepticus in children", section on 'Causes'</a> and  <a class="medical medical_review" href="/d/html/6218.html" rel="external">"Seizures and epilepsy in children: Clinical and laboratory diagnosis"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Freeman JM. Status epilepticus: it's not what we've thought or taught. Pediatrics 1989; 83:444.</a></li><li><a class="nounderline abstract_t">McKenzie KC, Hahn CD, Friedman JN. Emergency management of the paediatric patient with convulsive status epilepticus. Paediatr Child Health 2021; 26:50.</a></li><li><a class="nounderline abstract_t">Riviello JJ Jr, Ashwal S, Hirtz D, et al. Practice parameter: diagnostic assessment of the child with status epilepticus (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2006; 67:1542.</a></li><li><a class="nounderline abstract_t">Hanhan UA, Fiallos MR, Orlowski JP. Status epilepticus. Pediatr Clin North Am 2001; 48:683.</a></li><li><a class="nounderline abstract_t">Singh BM, Strobos RJ. Epilepsia partialis continua associated with nonketotic hyperglycemia: clinical and biochemical profile of 21 patients. Ann Neurol 1980; 8:155.</a></li><li><a class="nounderline abstract_t">Placidi F, Floris R, Bozzao A, et al. Ketotic hyperglycemia and epilepsia partialis continua. Neurology 2001; 57:534.</a></li><li><a class="nounderline abstract_t">Appleton R, Choonara I, Martland T, et al. The treatment of convulsive status epilepticus in children. The Status Epilepticus Working Party, Members of the Status Epilepticus Working Party. Arch Dis Child 2000; 83:415.</a></li><li><a class="nounderline abstract_t">Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012; 17:3.</a></li><li><a class="nounderline abstract_t">Glauser T, Shinnar S, Gloss D, et al. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr 2016; 16:48.</a></li><li><a class="nounderline abstract_t">Gaínza-Lein M, Sánchez Fernández I, Jackson M, et al. Association of Time to Treatment With Short-term Outcomes for Pediatric Patients With Refractory Convulsive Status Epilepticus. JAMA Neurol 2018; 75:410.</a></li><li><a class="nounderline abstract_t">Sánchez Fernández I, Abend NS, Agadi S, et al. Time from convulsive status epilepticus onset to anticonvulsant administration in children. Neurology 2015; 84:2304.</a></li><li><a class="nounderline abstract_t">Alldredge BK, Wall DB, Ferriero DM. Effect of prehospital treatment on the outcome of status epilepticus in children. Pediatr Neurol 1995; 12:213.</a></li><li><a class="nounderline abstract_t">Chin RF, Neville BG, Peckham C, et al. Treatment of community-onset, childhood convulsive status epilepticus: a prospective, population-based study. Lancet Neurol 2008; 7:696.</a></li><li><a class="nounderline abstract_t">McTague A, Martland T, Appleton R. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. Cochrane Database Syst Rev 2018; 1:CD001905.</a></li><li><a class="nounderline abstract_t">Chamberlain JM, Okada P, Holsti M, et al. Lorazepam vs diazepam for pediatric status epilepticus: a randomized clinical trial. JAMA 2014; 311:1652.</a></li><li><a class="nounderline abstract_t">Vasquez A, Gaínza-Lein M, Abend NS, et al. First-line medication dosing in pediatric refractory status epilepticus. Neurology 2020; 95:e2683.</a></li><li><a class="nounderline abstract_t">Chin RF, Verhulst L, Neville BG, et al. Inappropriate emergency management of status epilepticus in children contributes to need for intensive care. J Neurol Neurosurg Psychiatry 2004; 75:1584.</a></li><li><a class="nounderline abstract_t">Alshehri A, Abulaban A, Bokhari R, et al. Intravenous Versus Nonintravenous Benzodiazepines for the Cessation of Seizures: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Acad Emerg Med 2017; 24:875.</a></li><li><a class="nounderline abstract_t">Appleton R, Sweeney A, Choonara I, et al. Lorazepam versus diazepam in the acute treatment of epileptic seizures and status epilepticus. Dev Med Child Neurol 1995; 37:682.</a></li><li><a class="nounderline abstract_t">Chiulli DA, Terndrup TE, Kanter RK. The influence of diazepam or lorazepam on the frequency of endotracheal intubation in childhood status epilepticus. J Emerg Med 1991; 9:13.</a></li><li><a class="nounderline abstract_t">Qureshi A, Wassmer E, Davies P, et al. Comparative audit of intravenous lorazepam and diazepam in the emergency treatment of convulsive status epilepticus in children. Seizure 2002; 11:141.</a></li><li><a class="nounderline abstract_t">Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998; 339:792.</a></li><li><a class="nounderline abstract_t">Leppik IE, Derivan AT, Homan RW, et al. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 1983; 249:1452.</a></li><li><a class="nounderline abstract_t">Alldredge BK, Gelb AM, Isaacs SM, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 2001; 345:631.</a></li><li><a class="nounderline abstract_t">McDermott CA, Kowalczyk AL, Schnitzler ER, et al. Pharmacokinetics of lorazepam in critically ill neonates with seizures. J Pediatr 1992; 120:479.</a></li><li><a class="nounderline abstract_t">Greenblatt DJ, Shader RI, Franke K, et al. Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. J Pharm Sci 1979; 68:57.</a></li><li><a class="nounderline abstract_t">Relling MV, Mulhern RK, Dodge RK, et al. Lorazepam pharmacodynamics and pharmacokinetics in children. J Pediatr 1989; 114:641.</a></li><li><a class="nounderline abstract_t">Ahmad S, Ellis JC, Kamwendo H, Molyneux E. Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children: an open randomised trial. Lancet 2006; 367:1591.</a></li><li class="breakAll">Prescribing information Valtoco (diazepam nasal spray). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211635s000lbl.pdf (Accessed on January 15, 2020).</li><li><a class="nounderline abstract_t">McIntyre J, Robertson S, Norris E, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet 2005; 366:205.</a></li><li><a class="nounderline abstract_t">Alansari K, Barkat M, Mohamed AH, et al. Intramuscular Versus Buccal Midazolam for Pediatric Seizures: A Randomized Double-Blinded Trial. Pediatr Neurol 2020; 109:28.</a></li><li><a class="nounderline abstract_t">Silbergleit R, Durkalski V, Lowenstein D, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 2012; 366:591.</a></li><li><a class="nounderline abstract_t">Welch RD, Nicholas K, Durkalski-Mauldin VL, et al. Intramuscular midazolam versus intravenous lorazepam for the prehospital treatment of status epilepticus in the pediatric population. Epilepsia 2015; 56:254.</a></li><li class="breakAll">Prescribing information Nayzilam (midazolam) nasal spray. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211321s000lbl.pdf (Accessed on January 15, 2020).</li><li><a class="nounderline abstract_t">Maytal J, Novak G, Ascher C, Bienkowski R. Status epilepticus in children with epilepsy: the role of antiepileptic drug levels in prevention. Pediatrics 1996; 98:1119.</a></li><li><a class="nounderline abstract_t">Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998; 39:5.</a></li><li><a class="nounderline abstract_t">Tassinari CA, Dravet C, Roger J, et al. Tonic status epilepticus precipitated by intravenous benzodiazepine in five patients with Lennox-Gastaut syndrome. Epilepsia 1972; 13:421.</a></li><li><a class="nounderline abstract_t">Smith PE, McBride A. Illicit drugs and seizures. Seizure 1999; 8:441.</a></li><li><a class="nounderline abstract_t">Osorio I, Reed RC, Peltzer JN. Refractory idiopathic absence status epilepticus: A probable paradoxical effect of phenytoin and carbamazepine. Epilepsia 2000; 41:887.</a></li><li><a class="nounderline abstract_t">Chamberlain JM, Kapur J, Shinnar S, et al. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet 2020; 395:1217.</a></li><li><a class="nounderline abstract_t">Klowak JA, Hewitt M, Catenacci V, et al. Levetiracetam Versus Phenytoin or Fosphenytoin for Second-Line Treatment of Pediatric Status Epilepticus: A Meta-Analysis. Pediatr Crit Care Med 2021; 22:e480.</a></li><li><a class="nounderline abstract_t">Wills B, Erickson T. Chemically induced seizures. Clin Lab Med 2006; 26:185.</a></li><li><a class="nounderline abstract_t">Paloucek FP, Rodvold KA. Evaluation of theophylline overdoses and toxicities. Ann Emerg Med 1988; 17:135.</a></li><li><a class="nounderline abstract_t">Blake KV, Massey KL, Hendeles L, et al. Relative efficacy of phenytoin and phenobarbital for the prevention of theophylline-induced seizures in mice. Ann Emerg Med 1988; 17:1024.</a></li><li><a class="nounderline abstract_t">Kapur J, Elm J, Chamberlain JM, et al. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. N Engl J Med 2019; 381:2103.</a></li><li><a class="nounderline abstract_t">Dalziel SR, Borland ML, Furyk J, et al. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial. Lancet 2019; 393:2135.</a></li><li><a class="nounderline abstract_t">Lyttle MD, Rainford NEA, Gamble C, et al. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Lancet 2019; 393:2125.</a></li><li><a class="nounderline abstract_t">İşgüder R, Güzel O, Ceylan G, et al. A Comparison of Intravenous Levetiracetam and Valproate for the Treatment of Refractory Status Epilepticus in Children. J Child Neurol 2016; 31:1120.</a></li><li><a class="nounderline abstract_t">Abend NS, Dlugos DJ. Treatment of refractory status epilepticus: literature review and a proposed protocol. Pediatr Neurol 2008; 38:377.</a></li><li><a class="nounderline abstract_t">Reiter PD, Huff AD, Knupp KG, Valuck RJ. Intravenous levetiracetam in the management of acute seizures in children. Pediatr Neurol 2010; 43:117.</a></li><li><a class="nounderline abstract_t">Gallentine WB, Hunnicutt AS, Husain AM. Levetiracetam in children with refractory status epilepticus. Epilepsy Behav 2009; 14:215.</a></li><li><a class="nounderline abstract_t">Kim JS, Lee JH, Ryu HW, et al. Effectiveness of intravenous levetiracetam as an adjunctive treatment in pediatric refractory status epilepticus. Pediatr Emerg Care 2014; 30:525.</a></li><li><a class="nounderline abstract_t">Koul R, Deleu D. Subtherapeutic free phenytoin levels following fosphenytoin therapy in status epilepticus. Neurology 2002; 58:147.</a></li><li><a class="nounderline abstract_t">Uberall MA, Trollmann R, Wunsiedler U, Wenzel D. Intravenous valproate in pediatric epilepsy patients with refractory status epilepticus. Neurology 2000; 54:2188.</a></li><li><a class="nounderline abstract_t">Sofou K, Kristjánsdóttir R, Papachatzakis NE, et al. Management of prolonged seizures and status epilepticus in childhood: a systematic review. J Child Neurol 2009; 24:918.</a></li><li><a class="nounderline abstract_t">White JR, Santos CS. Intravenous valproate associated with significant hypotension in the treatment of status epilepticus. J Child Neurol 1999; 14:822.</a></li><li><a class="nounderline abstract_t">Donn SM, Grasela TH, Goldstein GW. Safety of a higher loading dose of phenobarbital in the term newborn. Pediatrics 1985; 75:1061.</a></li><li><a class="nounderline abstract_t">Tasker RC, Goodkin HP, Sánchez Fernández I, et al. Refractory Status Epilepticus in Children: Intention to Treat With Continuous Infusions of Midazolam and Pentobarbital. Pediatr Crit Care Med 2016; 17:968.</a></li><li><a class="nounderline abstract_t">Baumeister FA, Oberhoffer R, Liebhaber GM, et al. Fatal propofol infusion syndrome in association with ketogenic diet. Neuropediatrics 2004; 35:250.</a></li><li><a class="nounderline abstract_t">Rivera R, Segnini M, Baltodano A, Pérez V. Midazolam in the treatment of status epilepticus in children. Crit Care Med 1993; 21:991.</a></li><li><a class="nounderline abstract_t">Igartua J, Silver P, Maytal J, Sagy M. Midazolam coma for refractory status epilepticus in children. Crit Care Med 1999; 27:1982.</a></li><li><a class="nounderline abstract_t">Hanley DF, Kross JF. Use of midazolam in the treatment of refractory status epilepticus. Clin Ther 1998; 20:1093.</a></li><li><a class="nounderline abstract_t">Yoshikawa H, Yamazaki S, Abe T, Oda Y. Midazolam as a first-line agent for status epilepticus in children. Brain Dev 2000; 22:239.</a></li><li><a class="nounderline abstract_t">Papavasiliou AS, Kotsalis C, Paraskevoulakos E, et al. Intravenous midazolam in convulsive status epilepticus in children with pharmacoresistant epilepsy. Epilepsy Behav 2009; 14:661.</a></li><li><a class="nounderline abstract_t">Hanna JP, Ramundo ML. Rhabdomyolysis and hypoxia associated with prolonged propofol infusion in children. Neurology 1998; 50:301.</a></li><li><a class="nounderline abstract_t">Stelow EB, Johari VP, Smith SA, et al. Propofol-associated rhabdomyolysis with cardiac involvement in adults: chemical and anatomic findings. Clin Chem 2000; 46:577.</a></li><li><a class="nounderline abstract_t">Hemphill S, McMenamin L, Bellamy MC, Hopkins PM. Propofol infusion syndrome: a structured literature review and analysis of published case reports. Br J Anaesth 2019; 122:448.</a></li><li><a class="nounderline abstract_t">van Gestel JP, Blussé van Oud-Alblas HJ, Malingré M, et al. Propofol and thiopental for refractory status epilepticus in children. Neurology 2005; 65:591.</a></li><li><a class="nounderline abstract_t">Höfler J, Trinka E. Lacosamide as a new treatment option in status epilepticus. Epilepsia 2013; 54:393.</a></li><li><a class="nounderline abstract_t">Miró J, Toledo M, Santamarina E, et al. Efficacy of intravenous lacosamide as an add-on treatment in refractory status epilepticus: a multicentric prospective study. Seizure 2013; 22:77.</a></li><li><a class="nounderline abstract_t">Sutter R, Marsch S, Rüegg S. Safety and efficacy of intravenous lacosamide for adjunctive treatment of refractory status epilepticus: a comparative cohort study. CNS Drugs 2013; 27:321.</a></li><li><a class="nounderline abstract_t">Shiloh-Malawsky Y, Fan Z, Greenwood R, Tennison M. Successful treatment of childhood prolonged refractory status epilepticus with lacosamide. Seizure 2011; 20:586.</a></li><li><a class="nounderline abstract_t">Jain V, Harvey AS. Treatment of refractory tonic status epilepticus with intravenous lacosamide. Epilepsia 2012; 53:761.</a></li><li><a class="nounderline abstract_t">Poddar K, Sharma R, Ng YT. Intravenous Lacosamide in Pediatric Status Epilepticus: An Open-Label Efficacy and Safety Study. Pediatr Neurol 2016; 61:83.</a></li><li><a class="nounderline abstract_t">Grosso S, Zamponi N, Bartocci A, et al. Lacosamide in children with refractory status epilepticus. A multicenter Italian experience. Eur J Paediatr Neurol 2014; 18:604.</a></li><li><a class="nounderline abstract_t">Kahriman M, Minecan D, Kutluay E, et al. Efficacy of topiramate in children with refractory status epilepticus. Epilepsia 2003; 44:1353.</a></li><li><a class="nounderline abstract_t">Blumkin L, Lerman-Sagie T, Houri T, et al. Pediatric refractory partial status epilepticus responsive to topiramate. J Child Neurol 2005; 20:239.</a></li><li><a class="nounderline abstract_t">Perry MS, Holt PJ, Sladky JT. Topiramate loading for refractory status epilepticus in children. Epilepsia 2006; 47:1070.</a></li><li><a class="nounderline abstract_t">Gaspard N, Foreman B, Judd LM, et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia 2013; 54:1498.</a></li><li><a class="nounderline abstract_t">Jacobwitz M, Mulvihill C, Kaufman MC, et al. Ketamine for Management of Neonatal and Pediatric Refractory Status Epilepticus. Neurology 2022; 99:e1227.</a></li><li><a class="nounderline abstract_t">Buratti S, Giacheri E, Palmieri A, et al. Ketamine as advanced second-line treatment in benzodiazepine-refractory convulsive status epilepticus in children. Epilepsia 2023; 64:797.</a></li><li><a class="nounderline abstract_t">Cobo NH, Sankar R, Murata KK, et al. The ketogenic diet as broad-spectrum treatment for super-refractory pediatric status epilepticus: challenges in implementation in the pediatric and neonatal intensive care units. J Child Neurol 2015; 30:259.</a></li><li><a class="nounderline abstract_t">O'Connor SE, Ream MA, Richardson C, et al. The ketogenic diet for the treatment of pediatric status epilepticus. Pediatr Neurol 2014; 50:101.</a></li><li><a class="nounderline abstract_t">Cervenka MC, Hartman AL, Venkatesan A, et al. The ketogenic diet for medically and surgically refractory status epilepticus in the neurocritical care unit. Neurocrit Care 2011; 15:519.</a></li><li><a class="nounderline abstract_t">Chen J, Xie L, Hu Y, et al. Nonconvulsive status epilepticus after cessation of convulsive status epilepticus in pediatric intensive care unit patients. Epilepsy Behav 2018; 82:68.</a></li><li><a class="nounderline abstract_t">Tay SK, Hirsch LJ, Leary L, et al. Nonconvulsive status epilepticus in children: clinical and EEG characteristics. Epilepsia 2006; 47:1504.</a></li><li><a class="nounderline abstract_t">Jette N, Claassen J, Emerson RG, Hirsch LJ. Frequency and predictors of nonconvulsive seizures during continuous electroencephalographic monitoring in critically ill children. Arch Neurol 2006; 63:1750.</a></li><li><a class="nounderline abstract_t">Abend NS, Arndt DH, Carpenter JL, et al. Electrographic seizures in pediatric ICU patients: cohort study of risk factors and mortality. Neurology 2013; 81:383.</a></li><li><a class="nounderline abstract_t">Fung FW, Jacobwitz M, Vala L, et al. Electroencephalographic seizures in critically ill children: Management and adverse events. Epilepsia 2019; 60:2095.</a></li><li><a class="nounderline abstract_t">Singh RK, Stephens S, Berl MM, et al. Prospective study of new-onset seizures presenting as status epilepticus in childhood. Neurology 2010; 74:636.</a></li><li><a class="nounderline abstract_t">Yoong M, Madari R, Martinos M, et al. The role of magnetic resonance imaging in the follow-up of children with convulsive status epilepticus. Dev Med Child Neurol 2012; 54:328.</a></li></ol></div><div id="topicVersionRevision">Topic 6192 Version 61.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2919146" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Status epilepticus: it's not what we've thought or taught.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33552322" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Emergency management of the paediatric patient with convulsive status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17101884" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Practice parameter: diagnostic assessment of the child with status epilepticus (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11411300" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6775582" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Epilepsia partialis continua associated with nonketotic hyperglycemia: clinical and biochemical profile of 21 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11502930" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Ketotic hyperglycemia and epilepsia partialis continua.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11040151" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The treatment of convulsive status epilepticus in children. The Status Epilepticus Working Party, Members of the Status Epilepticus Working Party.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22528274" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Guidelines for the evaluation and management of status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26900382" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29356811" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Association of Time to Treatment With Short-term Outcomes for Pediatric Patients With Refractory Convulsive Status Epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25948729" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Time from convulsive status epilepticus onset to anticonvulsant administration in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7619187" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effect of prehospital treatment on the outcome of status epilepticus in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18602345" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Treatment of community-onset, childhood convulsive status epilepticus: a prospective, population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29320603" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24756515" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Lorazepam vs diazepam for pediatric status epilepticus: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32913024" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : First-line medication dosing in pediatric refractory status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15489391" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Inappropriate emergency management of status epilepticus in children contributes to need for intensive care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28342192" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Intravenous Versus Nonintravenous Benzodiazepines for the Cessation of Seizures: A Systematic Review and Meta-analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7672465" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Lorazepam versus diazepam in the acute treatment of epileptic seizures and status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2045642" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The influence of diazepam or lorazepam on the frequency of endotracheal intubation in childhood status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12018955" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Comparative audit of intravenous lorazepam and diazepam in the emergency treatment of convulsive status epilepticus in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9738086" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6131148" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Double-blind study of lorazepam and diazepam in status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11547716" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1538303" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pharmacokinetics of lorazepam in critically ill neonates with seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31453" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2926577" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Lorazepam pharmacodynamics and pharmacokinetics in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16698412" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children: an open randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16698412" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children: an open randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16023510" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32387007" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Intramuscular Versus Buccal Midazolam for Pediatric Seizures: A Randomized Double-Blinded Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22335736" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Intramuscular versus intravenous therapy for prehospital status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25597369" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Intramuscular midazolam versus intravenous lorazepam for the prehospital treatment of status epilepticus in the pediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25597369" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Intramuscular midazolam versus intravenous lorazepam for the prehospital treatment of status epilepticus in the pediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8951262" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Status epilepticus in children with epilepsy: the role of antiepileptic drug levels in prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9578007" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Antiepileptic drugs as a cause of worsening seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4626571" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Tonic status epilepticus precipitated by intravenous benzodiazepine in five patients with Lennox-Gastaut syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10627404" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Illicit drugs and seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10897162" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Refractory idiopathic absence status epilepticus: A probable paradoxical effect of phenytoin and carbamazepine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32203691" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33710073" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Levetiracetam Versus Phenytoin or Fosphenytoin for Second-Line Treatment of Pediatric Status Epilepticus: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16567231" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Chemically induced seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3276248" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Evaluation of theophylline overdoses and toxicities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3177989" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Relative efficacy of phenytoin and phenobarbital for the prevention of theophylline-induced seizures in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31774955" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31005386" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31005385" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27080042" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A Comparison of Intravenous Levetiracetam and Valproate for the Treatment of Refractory Status Epilepticus in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18486818" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Treatment of refractory status epilepticus: literature review and a proposed protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20610122" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Intravenous levetiracetam in the management of acute seizures in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18926926" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Levetiracetam in children with refractory status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25062293" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Effectiveness of intravenous levetiracetam as an adjunctive treatment in pediatric refractory status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11781425" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Subtherapeutic free phenytoin levels following fosphenytoin therapy in status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10851397" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Intravenous valproate in pediatric epilepsy patients with refractory status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19332572" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Management of prolonged seizures and status epilepticus in childhood: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10614572" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Intravenous valproate associated with significant hypotension in the treatment of status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4000780" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Safety of a higher loading dose of phenobarbital in the term newborn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27500721" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Refractory Status Epilepticus in Children: Intention to Treat With Continuous Infusions of Midazolam and Pentobarbital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15328567" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Fatal propofol infusion syndrome in association with ketogenic diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8319479" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Midazolam in the treatment of status epilepticus in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10507628" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Midazolam coma for refractory status epilepticus in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9916604" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Use of midazolam in the treatment of refractory status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10838111" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Midazolam as a first-line agent for status epilepticus in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19236944" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Intravenous midazolam in convulsive status epilepticus in children with pharmacoresistant epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9443502" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Rhabdomyolysis and hypoxia associated with prolonged propofol infusion in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10759487" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Propofol-associated rhabdomyolysis with cardiac involvement in adults: chemical and anatomic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30857601" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Propofol infusion syndrome: a structured literature review and analysis of published case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16116121" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Propofol and thiopental for refractory status epilepticus in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23293881" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Lacosamide as a new treatment option in status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23127776" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Efficacy of intravenous lacosamide as an add-on treatment in refractory status epilepticus: a multicentric prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23533010" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Safety and efficacy of intravenous lacosamide for adjunctive treatment of refractory status epilepticus: a comparative cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21474342" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Successful treatment of childhood prolonged refractory status epilepticus with lacosamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22462573" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Treatment of refractory tonic status epilepticus with intravenous lacosamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27241232" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Intravenous Lacosamide in Pediatric Status Epilepticus: An Open-Label Efficacy and Safety Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24836405" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Lacosamide in children with refractory status epilepticus. A multicenter Italian experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14510830" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Efficacy of topiramate in children with refractory status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15832617" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Pediatric refractory partial status epilepticus responsive to topiramate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16822255" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Topiramate loading for refractory status epilepticus in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23758557" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35817569" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Ketamine for Management of Neonatal and Pediatric Refractory Status Epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36792542" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Ketamine as advanced second-line treatment in benzodiazepine-refractory convulsive status epilepticus in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24464515" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The ketogenic diet as broad-spectrum treatment for super-refractory pediatric status epilepticus: challenges in implementation in the pediatric and neonatal intensive care units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24287234" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The ketogenic diet for the treatment of pediatric status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21523523" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The ketogenic diet for medically and surgically refractory status epilepticus in the neurocritical care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29587188" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Nonconvulsive status epilepticus after cessation of convulsive status epilepticus in pediatric intensive care unit patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16981867" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Nonconvulsive status epilepticus in children: clinical and EEG characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17172615" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Frequency and predictors of nonconvulsive seizures during continuous electroencephalographic monitoring in critically ill children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23794680" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Electrographic seizures in pediatric ICU patients: cohort study of risk factors and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31538340" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Electroencephalographic seizures in critically ill children: Management and adverse events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20089940" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Prospective study of new-onset seizures presenting as status epilepticus in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22268666" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The role of magnetic resonance imaging in the follow-up of children with convulsive status epilepticus.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
